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AICD, the C-terminal tail generated from the proteolytic cleavage of the Amyloid 
Precursor Protein (APP), has been generating interest for its transcriptional 
modulatory roles. AICD has been hypothesized to have such a function as it is 
generated by a γ-secretase-mediated regulated intramembrane proteolysis step, 
analogous to the generation of Notch intracellular domain (NICD), a well-known 
transcriptional regulator, from Notch. The AICD/Fe65/Tip60 ternary complex has 
been proposed as the working transcriptional regulatory complex and some of its 
target genes have been reported. However, our knowledge of the functions of AICD is 
still limited due to difficulties in detecting and manipulating the rapidly degraded 
peptide. Looking at AICD transcription modulation targets from a genome-wide 
perspective will aid our understanding of the role of AICD tremendously. To this end, 
AICD chromatin binding sites were investigated from a genome-wide perspective by 
performing Chromatin Immunoprecipitation coupled to deep DNA sequencing (ChIP-
Seq) in SH-SY5Y cells stably over-expressing APP/AICD. Computational analysis 
revealed multiple highly significant DNA motifs that were enriched at the AICD 
binding sites, indicating that AICD may work with different partner transcription 
factors to regulate different subsets of target genes. Additionally, gene expression 
profiling of SH-SY5Y cells revealed genes that were differentially expressed with 
varying APP/AICD levels. The expression profile was used to complement the AICD 
chromatin binding profile to identify genes that are both bound and regulated by 
AICD. Since AICD has been found to be elevated in patients suffering from 
Alzheimer’s Disease (AD) and may play a role in AD pathology, this study 
contributes to further insight into the potential role that AICD transcriptional 
modulation may have with respect to AD development. 
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1.1 Alzheimer’s Disease 
With the advancement of medical technology and the resultant increase in life 
expectancy, the world is now facing an ever-growing greying population. One major 
issue that stems from this is the rise in diseases and illnesses that afflict the aged. A 
rising concern is Alzheimer’s Disease (AD), a debilitating neurodegenerative disease 
first described by Alois Alzheimer, a German psychiatrist and neuropathologist, in 
1907. AD predominantly affects people above the age of 65 (Brookmeyer et al., 
1998), although 5-10% of AD cases are of the early-onset form, afflicting its sufferers 
before the age of 65. It is the most common form of senile dementia, with patchy 
memory loss in the initial stages progressing to cognitive and behavioural changes 
such as increased confusion, personality and mood changes, difficulty in 
understanding and expressing language, and unusual reasoning. At the most severe 
stages, patients lose recognition, are unable to care for themselves and suffer from 
incontinence and swallowing problems. Ultimately, they die from infections or 
pneumonia. The average life expectancy of an AD patient from the time of diagnosis 
is about seven years (Mölsä et al., 1986), although this varies and some live for as 
long as a decade.   
Unfortunately, there is currently no cure for AD. Medications such as Donepezil, 
Rivastigmine and Galantamine (acetylcholinesterase inhibitors) and Memantine 
(NMDA receptor antagonist), which are the only drugs approved to be prescribed for 
AD treatment, are only slightly beneficial for alleviating the symptoms of AD and 
remain largely palliative. As such, it exerts as much a physical and mental toll for the 
patient’s caretakers and loved ones as it does for the patient. Furthermore, the 
economic impact to society, especially in developed countries, cannot be ignored.  
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The most obvious pathological hallmarks of AD, as described by Alois Alzheimer, 
are the intracellular neurofibrillary tangles (NFTs) and extracellular amyloid plaques 
observed at the microscopic level in brain tissue. The prevailing theory for the cause 
of AD centres around the amyloid hypothesis, which suggests that abnormally folded 
amyloid beta (Aβ) protein formed via the amyloidogenic cleavage of the amyloid 
precursor protein (APP) accumulates outside neurons as senile plaques and leads to 
synapse loss and neuronal cell death (Glenner and Wong, 1984; Kang et al., 1987; 
Tanzi et al., 1988). Another contributor to the widespread neuronal cell death is the 
formation of NFTs by hyperphosphorylated microtubule-binding protein tau within 
the cell bodies of neurons, resulting in the obstruction of the neuronal transport 
system and eventually causing the death of neurons. It has since been shown that APP 
plays a part in the aggregation of the tau protein into NFTs (Götz et al., 2001; Lewis 
et al., 2001).  
 
1.2 The genetic basis of AD 
AD is a multifactorial disease that can only be explained in part by direct genetic 
factors. Sporadic forms of AD account for the vast majority of AD cases, while only a 
small percentage are of the familial type, exhibiting autosomal-dominant inheritance. 
Most mutations associated with early-onset familial AD (FAD) are attributable to the 
APP, presenilin 1 (PSEN1), and presenilin 2 (PSEN2) genes while the ε4 allele of the 
apolipoprotein E (APOE) gene is a well-known susceptibility factor for late-onset AD 




The APP gene is located on chromosome 21 and its mRNA undergoes alternative 
splicing to produce three APP isoforms: APP695, APP751 and APP770. Of these, 
APP695 is the predominant isoform expressed in brain tissues. APP is the protein 
central to the pathogenic process of AD and is a type I transmembrane glycoprotein 
involved in functions such as cell adhesion, synaptic transmission and plasticity, and 
learning and memory. It has a large extracellular N-terminal domain, a membrane-
anchoring domain and a much shorter intracellular C-terminal tail. Post-translational 
modifications that APP undergoes include N-glycosylation, O-glycosylation, and 
tyrosine sulphation. At the cell membrane, APP undergoes a series of proteolytic 
processing via two alternative pathways: the amyloidogenic or the non-amyloidogenic 
pathway, to give rise to multiple cleavage products (Fig.1). The amyloidogenic 
cleavage pathway involves cleavage at the extracellular side by β-secretase, also 
known as the β-site APP-cleaving enzyme (BACE), releasing a secreted form of APP 
(sAPPβ) and the membrane-associated C-terminal fragment (C99). A second cleavage 
step known as regulated intramembrane proteolysis (RIP) by the γ-secretase complex 
produces the Aβ fragment and APP intracellular domain (AICD). On the other hand, 
the non-amyloidogenic pathway involves cleavage by the α-secretase enzyme, which 
is likely to be one or more members of the ADAM metalloprotease family, instead of 
β-secretase at a cleavage site within the Aβ sequence (Esch et al., 1990). The secreted 
sAPPα and C83 membrane-associated fragments are produced instead, followed by 
the same γ-secretase complex cleavage to give rise to a p3 fragment and AICD. γ-
secretase, which is the enzymatic complex common to both proteolytic pathways, is a 
multimeric intramembranous complex composed of nicastrin (NCSTN), anterior 
pharynx defective 1 (APH1), presenilin 1 (PSEN1) and/or presenilin 2 (PSEN2) and 
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presenilin enhancer 2 (PEN2) (Edbauer et al., 2003). 
 
 
Figure 1. Proteolytic processing of APP. APP can be processed via the non-amyloidogenic 
or amyloidogenic pathways by an initial cleavage by α- or β-secretase respectively, followed 
by a second cleavage by γ-secretase in both pathways. An intracellular C-terminal domain 
(AICD) is formed in both cases. (Adapted from Buoso et al., 2010) 
 
1.2.2 Aβ  in AD 
It is through the amyloidogenic APP proteolytic pathway that Aβ is produced. The 
Aβ peptides are mainly 39-43 amino acids long, and are found in fibrillar deposits 
called amyloid plaques, consisting of β-sheet structures. At normal physiological 
concentrations, Aβ has neurotrophic effects while this effect is reversed by its over-
accumulation (Yankner et al., 1990). The γ-secretase enzymatic complex can cleave 
the C99 fragment produced in the process of amyloidogenic proteolysis at three 
possible sites: γ, ζ or ε. The most commonly generated Aβ fragments, Aβ40 and 
Aβ42, are formed when cleavage at either amino acid 40 or 42 of the γ site occurs. 
With relevance to AD, a higher proportion of the Aβ42 species as compared to the 
Aβ40 species has been found to be related to a higher risk of amyloid plaque 
accumulation (Haass et al., 2007). A telling piece of evidence for the involvement of 
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Aβ42 accumulation in AD is that the Aβ42 peptide is found to be up-regulated in 
some AD-causing mutations found in APP, PSEN1 and PSEN2 (Scheuner et al., 
1996). The biochemical basis of this is that Aβ42 is more hydrophobic than Aβ40, 
owing to its alanine and isoleucine residues at the C-terminal. Hence, the stable 
accumulation of trimeric and tetrameric oligomers can occur more easily and rapidly 
(Chen and Glabe, 2006). In accordance, the rise in Aβ40 peptide levels in transgenic 
mice did not cause amyloid plaque formation but instead impeded the aggregation of 
Aβ42 (McGowan et al., 2005).  
 
For all the studies performed to prove Aβ as the causal factor of AD pathogenesis, the 
amyloid theory remains a hypothesis due to incongruent findings. APP transgenic 
mice displaying AD-like impairments in memory, synaptic loss and 
neurodegeneration did not show a corresponding accumulation of Aβ42 although 
there was correlation with tau pathology (Simón et al., 2009). In addition, other 
mouse models showed similar impairment of memory without the observation of Aβ 
plaques (Lesne et al., 2008). More relevantly, there is poor correlation between Aβ 
plaque accumulation and the severity of disease in AD patients (Terry et al., 1991). 
Surprisingly, plaque formation was revealed by in vivo neuroimaging techniques even 
in non-dementia subjects (Nordberg, 2008; Villemagne et al., 2008). Further, if Aβ is 
indeed the causative agent of AD, the clearance of Aβ by immunization should offer 
some therapeutic benefits in AD patients. However, this was not the case in a phase I 
trial by Holmes et al. (2008) in which Aβ plaque clearance did not prevent the 
development of severe dementia. The limited success in this and other clinical trials 
targeting Aβ is perhaps an indication that there might be other factors involved in the 
development of AD. 
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1.3 AICD  
1.3.1 Production and degradation 
Much of the research surrounding AD has traditionally been focused on the role of 
Aβ. Although there has been increasing interest in AICD ever since it was first 
described in the guinea pig brain (Pinnix et al., 2001), the progress in our knowledge 
of AICD has been limited. AICD, as mentioned previously, is the 6kDa C-terminal 
fragment produced upon γ-secretase cleavage at the ε-site at amino acid 49 of APP. 
Interestingly, the AICD region of APP is the most highly conserved in terms of amino 
acid sequence. There is complete conservation among the human, mouse, rat and 
chicken amino acid sequences whereas the human and Xenopus/zebrafish sequences 
differ by only two or three amino acids (Fig. 2A). Comparatively, the Aβ amino acid 
sequence is not as well-conserved (Fig. 2B) (Nakayama et al., 2008). This level of 
conservation strongly points to AICD being functionally important. 
 
 
Figure 2. Conservation of AICD and Aβ42 amino acid sequences. Amino acid sequence 
alignment of (A) AICD and (B) Aβ42 regions of APP in human (H), mouse (M), rat (R), 
chicken (C), Xenopus (X) and zebrafish (Z). (Adapted from Nakayama et al., 2008)   
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AICD50 is the main form of AICD that was detected by mass spectroscopy in 
neuroblastoma cells (Yu et al., 2001). Other species detected include AICD48 and 
AICD51 (Yu et al., 2001; Sato et al., 2003) whereas AICD59 and AICD57, the 
species that should theoretically be present after the release of Aβ40 and Aβ42 
respectively, have not yet been detected unambiguously by mass spectrometry. 
Additionally, caspase cleavage of AICD releases an AICD31 fragment that induces 
apoptosis (Lu et al., 2000).  
 
It has been postulated that both the γ- and ε-cleavage is attributed to the same 
proteolytic activity by γ-secretase, indicating that there should be equimolar amounts 
of Aβ and AICD formation (Kakuda et al., 2006). Moreover, both Aβ and AICD 
levels are increased in most of the PSEN1 and PSEN2 mutations, indicating that the 
disruption of normal γ-secretase function affects both peptide species similarly (Sato 
et al., 2003). Other studies, on the other hand, have shown that a particular PSEN1 
mutation influences the generation of AICD and Aβ differently (Moehlmann et al., 
2002), and that while APP mutations can have an effect on the Aβ42 levels, not all of 
the mutations affect the generation of AICD (Hecimovic et al., 2004). Evidence that 
the production of AICD and Aβ is modulated differentially lie in the observation that 
TMP21 (21kDa transmembrane protein) can decrease Aβ levels with AICD levels 
unaffected (Chen et al., 2006), and in the manner that Fe65 (APP-binding protein) 
elevates AICD levels while reducing Aβ42 levels at the same time (Wiley et al., 
2007).  
 
One of the reasons for the poor documentation of AICD is the difficulty of detecting 
and studying the peptide. It is small and highly labile with a short half-life of 5 
 9 
minutes (Cupers et al., 2001) and is rapidly degraded by the insulin-degrading 
enzyme (IDE) (Edbauer et al., 2002). As such, its steady-state levels are extremely 
low, precluding its reliable detection. Wild-type IDE, when overexpressed, was able 
to enhance AICD degradation. However, this effect was nullified with a catalytically 
inactive form of IDE (Edbauer et al., 2002). IDE also contributes to AICD 
degradation in vivo since IDE-depleted mice showed an increase in AICD levels 
(Farris et al., 2003). Studies involving IDE have linked it to AD pathology. In the 
human hippocampus, IDE levels were observed to decrease with aging (Caccamo et 
al., 2005) while a similar change in IDE levels was also detected in AD transgenic 
mice models (Hwang et al., 2005). This points to the possibility that a drop in AICD 
degradation by IDE could contribute to AICD accumulation and, hence, AD 
pathology. 
 
The endosomal/lysosomal system has also been associated with AICD degradation 
since alkalizing drugs were observed to promote the accumulation of AICD 
(Vingtdeux et al., 2007). The pH of intracellular compartments is important for 
optimal enzymatic function and altering it would impair AICD degradation in via the 
endosomal/lysosomal pathway. 
  
1.3.2 Functions of AICD 
AICD has long been hypothesized as an intracellular signaling molecule that 
transduces signals from the cell membrane into the nucleus to regulate gene 
expression. The transient nature of AICD may make its study complicated, but it is a 
strong indicator that AICD participates in intracellular signaling. The initial 
hypothesis that AICD has such a function is due to its analogy to the Notch 
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intracellular domain (NICD). This stems from the fact that APP is processed in a 
similar way as Notch, another type I transmembrane protein, by γ-secretase (Kimberly 
et al., 2001). Like APP, Notch is processed by two sequential cleavages, first by the 
metalloprotease, ADAM17, after which γ-secretase cleaves and releases NICD. The 
S3-hydrolysis of Notch and the ε-cleavage of APP, which release NICD and AICD, 
respectively, are seen as similar processes. In the nucleus, NICD associates with the 
transcriptional repressor CSL (CBF1/ RBPJκ in vertebrates, suppressor of hairless in 
Drosophila, Lag-1 in C. elegans) to lift its repression of target genes like the basic 
helix-loop-helix (bHLH) HES (Hairy/Enhancer of Split) family of transcriptional 
regulators. Since NICD has a transcriptional modulation function, AICD could have a 
similar role as an intracellular signaling molecule that could regulate transcription (De 
Strooper et al., 1999; Schroeter et al., 1998). Furthermore, the transient nature of 
AICD may be a strong indication of its functions as a transcriptional signaling 
molecule, due to its ability to quickly react to changing signaling landscapes. 
 
Indeed, studies have shown AICD to be active in transcriptional regulation. The first 
such report by Cao and Südhof (2001) showed that AICD that was fused with N-
terminal Gal4 could interact with the Gal4 response element and activate the 
expression of a luciferase reporter by acting in a transcriptional complex comprising 
of Fe65 (an adaptor protein) and Tip60 (a histone acetyltransferase). However, the 
luciferase reporter system utilized in the study does not prove unequivocally that 
AICD translocates into the nucleus. Fe65 is the adaptor protein that binds and 
stabilizes AICD in the cytoplasm, before promoting AICD nuclear translocation 
(Kimberly et al., 2001). AICD binds Fe65 via a highly conserved YENPTY motif on 
AICD, which Fe65 recognises via its phosphotyrosine-binding domain 2 (PTB2) 
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(Borg et al., 1996). In the Cao and Südhof (2001) study, Fe65 greatly increased the 
transcriptional activation potential of AICD, which was reversed when the NPTY 
motif on AICD was mutated. Once in the nucleus, AICD and Fe65 then bind Tip60 
via interaction between Tip60 and the phosphotyrosine-binding domain 1 (PTB1) of 
Fe65, forming a multiprotein complex that binds chromatin for transcriptional 
regulation (Fig. 3). Confocal microscopy techniques identified AFT 
(AICD/Fe65/Tip60) complexes that were mainly found in spherical nuclear spots, 
which are purported to be sites of active transcription as they are quite large and could 
contain additional molecules necessary for transcriptional activity (von Rotz et al., 
2004). Other than the AFT complex, AICD and Fe65 have also been observed to form 
a complex with the transcriptional activator CP2/LSF/LBP1, again via its interaction 
with the PTB1 of Fe65 (Zambrano et al., 1998). Accordingly, Kim et al. (2003) 
showed that the AICD-Fe65-CP2/LSF/LBP1 ternary complex was essential for the 
up-regulation of glycogen synthase kinase 3β (GSK3β), a proline-directed 
serine/threonine kinase, which has been identified as an AICD transcriptional target.  
 
NICD is released from Notch via γ-secretase cleavage that is promoted by the binding 
of Notch ligands, which are proteins of the DSL ((Delta and Serrate/Jagged in 
Drosophila and vertebrates, Lag-2 in C. elegans) family (Selkoe and Kopan, 2003). 
Therefore, RIP of APP to release AICD could be stimulated by a ligand of APP. 
TAG1, a cell membrane-anchored glycophosphatidylinositol-linked protein, has 
recently been discovered as a functional ligand of APP (Ma et al., 2008). Authors of 
the study showed that the TAG1-APP interaction was able to promote the Fe65-
dependent release of AICD. Furthermore, the released AICD had a negative 
modulatory effect on neurogenesis. This was evident as primary neural stem cells 
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harvested from TAG1 knockout mice displayed up-regulated neurogenesis, which 
was reversed by the transfection of AICD (Ma et al., 2008). The findings shed some 
light on the regulation of AICD release and also provided clues to the physiological 







Figure 3. The AFT ternary complex in transcription. TAG1-triggered regulated 
intramembrane proteolysis (RIP) by γ-secretase releases AICD, which is stabilized and 
translocated into the nucleus with the help of Fe65, a multidomain adaptor protein. In the 
nucleus, Tip60 is recruited to form the AFT (AICD/Fe65/Tip60) multiprotein transcriptional 




1.3.3 AICD transcriptional targets 
A number of genes have been identified to be under the transcriptional control of 
AICD (Table 1) despite difficulties working with the ephemeral peptide. These 
include KAI1, neprilysin (NEP), p53, which are up-regulated by AICD, and EGFR 
and LRP1, which are down-regulated, among others. NEP, being an Aβ-degrading 
enzyme, drew much interest as a transcriptional target. AICD was shown to directly 
bind the NEP promoter by chromatin immunoprecipitation (ChIP) experiments 
(Belyaev et al., 2009). Moreover, the enrichment in AICD binding sites at the NEP 
promoter was negated by the addition of a γ-secretase inhibitor, which blocks the 
generation of AICD (Belyaev et al., 2009). These findings correlate with another 
study by Pardossi-Piquard et al. (2005), showing that AICD induces NEP expression. 
As mentioned previously, Kim et al. (2003) showed via luciferase activity assays that 
GSK3β promoter activity was increased upon wild-type AICD transfection whereas 
this effect was not observed when deletion and functional mutants of AICD were 
transfected. This, along with in vivo evidence that GSK3β is activated in AICD 
transgenic mice (Ryan and Pimplikar, 2005), suggests the involvement of AICD in 
GSK3β regulation. Similar luciferase assays indicate that AICD positively regulates 
p53, as the transactivation of the p53 promoter is reduced upon presenilin deficiency 
or the addition of a γ-secretase inhibitor (Alves da Costa et al., 2006). Many more 
AICD targets have been identified, linking AICD to numerous cellular functions that 





Table 1. AICD target genes 
AICD target 
genes 





shift or ChIP 
experiments) 
References 
KAI1/CD82 Metastasis suppressor, 
apoptosis 
Up Yes Baek et 
al.,2002; von 
Rotz et al., 2004 
GSK3β Kinase, glycogen 
metabolism, cell 
development, cell cycle 
regulation, proliferation 
and apoptosis 
Up Unknown Kim et al., 
2003; von Rotz 
et al., 2004 




Up Unknown von Rotz et al., 
2004 
BACE Aspartyl protease, APP 
cleaving enzyme 
Up Unknown von Rotz et al., 
2004 
NEP Metallopeptidase, Aβ 
degrading enzyme 
Up Yes Pardossi-
Piquard et al., 
2005; Belyaev 
et al., 2009 
p53 Tumor suppressor, 
apoptosis 
Up Yes Alves da Costa 
et al., 2006; 
Ozaki et al., 
2006 
α2-Actin Organization and 
dynamics of the actin 
cytoskeleton 
Up Unknown Muller et al., 
2007 
Transgelin Organization and 
dynamics of the actin 
cytoskeleton 
Up Unknown Muller et al., 
2007 
IGFBP3 Transport of insulin 
growth factor 
Up Unknown Muller et al., 
2007 
EGFR Cell cycle, proliferation, 
differentiation, survival 
function 




Cell cycle activation Up Unknown Ahn et al., 2008 
CHOP ER stress, unfold 
protein response (UPR), 
apoptosis 
Up Yes Takahashi et al., 
2009 
APP, amyloid precursor protein; BACE, beta-site APP cleaving enzyme 1; CHOP, C/EBP 
homologous protein; EGFR, epidermal growth factor receptor; GSK3β, glycogen synthase 
kinase; IGFBP3, insulin growth factor-binding protein 3; NEP, neprilysin. 
 
(Adapted from Pardossi-Piquard and Checler, 2012.) 
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1.3.4 AICD binding proteins 
Other than Fe65 and CP2/LSF/LBP1, a number of studies report AICD binding to 
many other factors. The Mint/X11 adaptor family members bind to the YENPTY 
motif of AICD (Borg et al., 1996). In particular, the neuron-specific members, 
MINT1 and MINT2, were able to inhibit AICD transactivation in a Gal4 reporter 
system (Biederer et al., 2002). Contrary to the inhibitory effects of Mint family 
members, the Jip (c-Jun-N-terminal kinase interacting protein) family member, JIP1b, 
similarly binds the YENPTY motif of AICD (Matsuda et al., 2001) but induce 
transcription by AICD instead (Scheinfeld et al., 2003). Another corroborating study 
revealed that JIP1b forms nuclear AJT complexes with AICD and Tip60 that were 
localized to speckle-like structures morphologically different from the spherical spots 
that AFT complexes localize to (von Rotz et al., 2004). Based on this, the study 
suggested that the AFT and AJT complexes might be responsible for regulating 
distinctive sets of genes involved in different cellular functions. However, the AJT 
complexes were present in lower numbers than the AFT spots, indicating that AICD 
interacts predominantly with Fe65. Furthermore, in yeast two hybrid screens, Fe65 
was found to be the most frequent interactor of AICD (Bressler et al., 1996; Cao and 
Südhof, 2001). Additional binding proteins of AICD include members of the Shc 
family and mDab1 (Buoso et al., 2010) and so on. As such, the transcriptional 
functions of AICD may be activated or inhibited according to the proteins that it 
interacts with, although the general consensus is that Fe65 is still the main binding 




1.3.5 AICD signaling cross-talk 
With the many adaptor proteins that AICD binds to, and numerous other proteins that 
each adaptor could bind to, it is unsurprising that there could be cross-talk between 
the AICD signaling pathway and other proteins. APP competes with other RIP 
substrates for γ-secretase proteolytic activity and thus, its signaling activities may be 
somewhat dependent on these other RIP substrates. An example of this is Notch, 
which releases NICD upon γ-secretase cleavage. JIP1, an interacting protein of AICD 
which induces AICD transcription (Scheinfeld et al., 2003), is also bound and 
inhibited by NICD (Kim et al., 2005). Further, AICD binds the Notch inhibitor, 
Numb and down-regulates Notch signaling (Roncarati et al., 2002). A clue to the 
cross-talk between AICD and NICD is revealed by the presence of NICD in the 
nuclear spherical spots that contain the AFT complexes (Konietzko et al., 2010). In 
accordance with these findings, NICD was demonstrated to bind Fe65, the AICD-
binding protein. More significantly, this interaction was shown to have a function as 
NICD could transactivate the AICD target gene, KAI1, and AICD could reciprocally 
transactivate the NICD target gene, HES1 (Fischer et al., 2005). The physical 
interaction of NICD with the AFT complex may also play an inhibitory role in terms 
of AFT-mediated transcription, resulting in the suppression of AICD-induced 
production of reactive oxygen species (ROS) and cell death (Kim et al., 2007).      
Other than NICD, AICD transcriptional functions are influenced by other proteins 
like the estrogen receptor α (ERα), which complexes with Fe65 at the KAI1 gene 
promoter to reverse the positive modulatory effect of AICD signaling on KAI1 (Bao et 
al., 2007). In a similar manner, the Alcadein/Calsyntenin intracellular domain 
(AlcαICD) competes with AICD for binding to Fe65, and when bound, suppresses 
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gene transactivation by Fe65 (Araki et al., 2004). Evidently, there exist multiple 
interactions between AICD or its adaptors with other proteins that function to alter 
AICD signaling and the regulatory control of its target genes.  
 
1.4 Effects of AICD signaling on cellular functions  
1.4.1 AICD and cytoskeletal dynamics 
Studies have shown that AICD regulates genes associated with cytoskeletal dynamics. 
Using an inducible AICD and Fe65 expression system in neuroblastoma cells, Müller 
et al. (2007) identified a group of genes related to cytoskeletal functions, including 
α2-actin, Transgelin and Tropomyosin 1, that were up-regulated when AICD 
expression was induced. When AICD and Fe65 expression was induced at the same 
time, the up-regulation was further enhanced. The AICD-dependent changes in 
expression were correlated with AD as some of the identified genes, including α2-
actin and Transgelin, were found to be more highly expressed in the frontal cortex of 
AD patients (Müller et al., 2007). Moreover, Tropomyosin 1 was also observed to be 
differentially up-regulated in AD brains as compared to normal brains, and has been 
discovered in NFTs (Galloway et al., 1990), one of the pathological hallmarks of AD. 
According to Müller et al. (2007), the co-overexpression of AICD and Fe65 resulted 
in actin filaments losing their normal configuration in the cell body and clustering at 
the periphery instead in both human neuroblastoma cells and primary cortical neurons 
from mice. Transgelin is involved in actin cross-linking and stabilizes actin filaments 
in the organization of the cytoskeleton (Goodman et al., 2003) and Tropomyosin 1 
has similar roles as an actin-binding protein that provides stability for the cytoskeletal 
network. Since a decrease in spine density and changes in spine morphology in 
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neurons have been reported in AD (Penzes et al., 2011), it is likely that AICD 
signaling targets genes involved in cytoskeletal organization, disrupting the normal 
assembly of actin filaments and hence leading to the pathological manifestation of 
altered spine architecture.  
In a follow-up report investigating the effects of inducible AICD/Fe65 
overexpression, mitochondrial function was found to be disrupted, along with actin 
dynamics (Ward et al., 2010). Similar changes were observed with the overexpression 
of Transgelin. Specifically, a drop in the mitochondrial membrane potential, 
accompanied by decreases in ATP and basal superoxide levels, and the clumping of 
mitochondria in the perinuclear regions, were indicative of disrupted mitochondrial 
localization since this is dependent on normal cytoskeletal organization. These reports 
point to the possibility that neurodegeneration observed in AD can be explained by 
the disorganization of actin cytoskeleton.  
 
1.4.2 AICD and calcium homeostasis 
Yet another cellular function implicated in AD is the regulation of calcium 
homeostasis. Fibroblasts isolated from transgenic mice expressing mutant PSEN1, 
which is linked to some types of FAD, displayed elevated ER calcium levels, leading 
to disrupted influx of calcium from extracellular sources (Leissring et al., 2000). In a 
further study directly implicating APP and AICD, calcium signaling was impaired in 
fibroblasts from APP knockout mice, which was similarly observed in PSEN1 
knockout cells (Leissring et al., 2002). This impairment could be rescued by an 
overexpression of APP with an AICD tail but not when part of the AICD sequence 
was deleted, suggesting that AICD signaling could modulate calcium levels. 
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Interestingly, a study by Hamid et al. (2007) not only agreed with previous studies, 
but also showed that impaired calcium homeostasis due to AICD dysregulation was 
accompanied by changes in ATP levels and mitochondrial membrane potential, 
mimicking changes seen when oxidative phosphorylation that goes on in the 
mitochondria is disrupted. Hence, AICD signaling may regulate calcium homeostasis, 
which is reciprocally linked to mitochondrial functions (Carafoli, 2003). 
 
1.4.3 AICD and apoptosis 
The first report of AICD detection in AD patient brains revealed its role as an 
activator of apoptosis and can thus be linked to the neurodegeneration observed in AD 
(Passer et al., 2000). Many other studies have since linked AICD to the activation of 
apoptosis. The transfection of AICD led to signs of apoptosis including nuclear 
blebbing, which was blocked when nuclear translocation of AICD was inhibited and 
when Tip60 was mutated, showing that AICD signaling that leads to apoptosis is 
Tip60-dependent (Kinoshita et al., 2002). Tellingly, AICD-induced apoptosis is 
neuron-specific (Nakayama et al., 2008; Ohkawara et al., 2011). Hirano bodies, 
which are cytoplasmic inclusions present in neurodegenerative diseases including 
AD, were found to accumulate AICD and Fe65, preventing their nuclear localization 
which is necessary for participation in transcription regulation. The hirano bodies 
inhibited both AICD-mediated apoptosis and AICD/Fe65-dependent transcription, 
providing support to the association of AICD signaling to apoptosis (Ha et al., 
2010a). Effector caspase 6 and PRKC (prostate apoptosis response protein 4), which 
are implicated in apoptosis, were also differentially regulated with AICD 
overexpression (Müller et al., 2007). 
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Subsequent studies provided a better idea of the mechanisms behind AICD-mediated 
apoptosis. The tumour suppressor p53 is one of the AICD targets that could be 
involved in apoptosis induced by AICD. AICD not only binds to the p53 promoter 
and enhances its expression (Alves da Costa et al., 2006), it interacts with the p53 
protein as well, as shown in co-immunoprecipitation experiments carried out by 
Ozaki et al. (2006). This interaction was significant in mediating AICD-dependent 
apoptosis as more apoptotic activity was observed with both AICD and p53 being 
expressed as compared to p53 expression alone. Furthermore, AICD was unable to 
induce apoptosis in cells that did not express p53 (Ozaki et al., 2006). As such, it is 
probable that AICD induces apoptosis via p53 and p53 might even act as a co-
activator of AICD given the interaction between the two. 
Another contributor to AICD-mediated apoptosis is GSK3β, which was described as a 
transcriptional target of AICD. Upon overexpression of AICD, the enhanced 
expression of GSK3β by the transcriptional activity of the AICD-Fe65-
CP2/LSF/LBP1 ternary complex resulted in neurotoxicity in differentiated PC12 cells 
and rat primary cortical neurons (Kim et al., 2003). The neurotoxicity was also 
accompanied by decreased β-catenin levels, which has been shown to promote 
neuronal apoptosis (Zhang et al., 1998), and induced tau phosphorylation, which is 
one of the hallmarks of AD. The increase in GSK3β levels is similarly observed in 
AD brains, with GSK3β present in pretangle neurons (Pei et al., 1999). Hence, the 
mechanism of AICD-mediated apoptosis could be dependent on the regulation of 




1.4.4 AICD and cell cycle regulation  
Both in vitro and in vivo evidence has shown that cell cycle regulation in neurons is 
linked to AICD expression and this is associated with neurodegeneration seen in AD. 
Both mRNA and protein levels of cyclins B1 and D1 were differentially up-regulated 
in differentiated PC12 cells and rat primary cortical neurons overexpressing AICD 
(Ahn et al., 2008). These results corroborated investigations of AD patient brains, 
which showed abnormal expression of cyclin D, cdk4, proliferating cell nuclear 
antigen, and cyclin B1 in the hippocampus, subiculum, locus coeruleus, and dorsal 
raphe nuclei (Busser et al., 1998). The aberrant expression of cell cycle genes was 
linked to the actual anomaly in cell cycle processes in the human AD brain and FAD 
mouse models by fluorescence in situ hybridization (FISH) studies showing active 
DNA replication due to cell cycle re-entry up to the G2 phase (Yang et al., 2001; 
Yang et al., 2006). At this point, the neuronal cells are stuck and do not go through 
the M phase to resolve the cycle, likely leading to cell death. Differential cell cycle 
regulation in postmitotic neurons may in fact represent an early event that will later 
lead to neurodegeneration in AD (Nagy et al., 1997). Cell cycle factors can change 
the stability of microtubules and thus the phosphorylation state of the tau protein. 
Hence, cell cycle re-entry of neurons can lead to cytoskeletal changes, which can in 
turn be linked to AD pathogenesis.  
 
1.4.5 Possible function of AICD in synaptic plasticity  
Evidence from transgenic mouse models indicates a significant role of APP in 
synaptic plasticity, memory and long-term potentiation (LTP). The hippocampus of 
APP-null mice displayed aberrant neuronal morphology with abnormal staining for 
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pre- and post-synaptic markers, along with reduced dendritic length and projection 
depth of CA1 neurons, and impaired LTP, drawing the authors to the conclusion that 
synaptic plasticity is compromised due to the lack of APP function (Seabrook et al., 
1999). Behavioural studies substantiate the functions of APP as APP knockout mice 
consistently performed worse in their passive avoidance responses, which test the 
animals’ long-term memory for their ability to remember and avoid an undesirable 
event (Senechal et al., 2008). Notably, Fe65-null mice, like the APP-null mice, 
performed poorer in Morris water maze tests and passive avoidance tests, suggesting 
that they had problems with reversal learning, short-term memory and early-phase 
LTP (Wang et al., 2004; Wang et al., 2009). The fact that APP- and Fe65-null mice 
show similar AD-related defects strongly suggest that the molecular basis of the 
synaptic plasticity and memory impairments in fact lies in Fe65-dependent AICD 
nuclear signaling. An AD mouse model, PDAPP, provides clues that AICD does play 
an important role in maintaining synapses. A mutation in Asp664 of the APP 
transgene in PDAPP, which represents a caspase cleavage site that forms AICD31, 
was able to reverse the AD-like abnormalities like synaptic loss, atrophy of the 
dentate gyrus, increased neuronal precursor proliferation and behavioural changes 
observed in normal PDAPP mice. Moreover, the Aβ levels and plaque formation were 
not affected, suggesting that synaptic loss and other observations of AD pathogenesis 
may be more associated with AICD than Aβ (Galvan et al., 2006; Galvan et al., 2008; 
Saganich et al., 2006). 
Synaptic loss is also a sign of neurodegeneration, a key event in AD pathogenesis. 
Transgenic mice overexpressing AICD was observed to display pathological features 
that were reminiscent of AD pathology, including tau hyperphosphorylation and 
accumulation, neurodegeneration specifically in the hippocampal CA3 region, and 
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deficiencies in working memory (Ghosal et al., 2009). These observations were likely 
due to an increase in GSK3β, solely mediated by AICD since Aβ levels and APP 
metabolism were unchanged. This report additionally supports the link between 
GSK3β-mediated apoptosis, and neurodegeneration. As mentioned previously, 
neurogenesis, the only process that could reverse the damages of neuronal loss, is 
unfortunately also affected. This was shown in the ability of TAG1-induced AICD 
release to negatively regulate neurogenesis in an Fe65-dependent manner (Ma et al., 
2008).   
Taken together, cellular functions like cytoskeletal dynamics, cell cycle regulation, 
and apoptosis that are regulated by AICD and are dysregulated in AD seem to be 
interlinked. The observations of aberrant cellular functions may come together and in 















1.5 Experimental aims and approach 
 
AICD is a relatively new entrant into the field of AD. Even though many targets have 
been identified as being under its transcriptional control, not all studies show a direct 
interaction of the AICD transcriptional complex with target gene promoter regions at 
the chromatin level. Furthermore, our knowledge about the functions of AICD 
signaling is clearly limited. Even so, the combination of several observations allows 
us to form a hypothesis about AICD functions:  
1) Poor correlation of Aβ, the peptide central to the amyloid hypothesis and seen 
as the causal agent of AD, with AD pathogenesis. 
2) AICD expression is associated with neurodegeneration, a key occurrence in 
AD. 
3) AICD modulates the transcription of target genes. 
Thus, it is conceivable that AICD, by regulating the transcription of specific target 
genes, could lead to changes in cellular functions that may in turn contribute to AD 
pathogenesis. It would be interesting to further our understanding of AICD 
transcriptional regulation from a genome-wide perspective to elucidate the 
downstream cellular functions that are regulated.  
To this end, I aim to take a two-pronged approach to profile genome-wide AICD 
targets: 
1) AICD binding sites on chromatin, which represents gene regions where the 
AICD transcriptional complex may act at, can be identified using Chromatin 
Immunoprecipitation coupled to deep DNA sequencing (ChIP-Seq). 
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2) Gene expression analysis to reveal genes that are differentially regulated by 
AICD can complement the chromatin binding data and allow the identification 
of direct targets of AICD. 
The revelation of sets of genes regulated by AICD could provide clues to the 
downstream signaling effects that may lead to altered cellular functions. This will 
provide new insights on the molecular mechanisms that could explain AD 
pathogenesis. Such information will be highly valuable towards AD drug therapy as 





















CHAPTER 2:  











2.1 Cell culture 
2.1.1 Maintenance of cell lines 
The SH-SY5Y human neuroblastoma cell line was maintained in Dulbecco's modified 
Eagle's medium (DMEM) containing 4500mg/L glucose, supplemented with 10% 
heat inactivated FBS (Gibco), 110 mg/L sodium pyruvate (Gibco), 2 mM L-glutamine 
(Gibco), 100µm MEM non-essential amino acids (Gibco), and 1% penicillin 
streptomycin (Gibco). Cells were maintained as a monolayer culture at 37°C in a 5% 
CO2 incubator. Once confluent, cells were passaged at a ratio of about 1:6 according 
to the following steps. After aspiration of the cell culture media, the cells were rinsed 
twice with 1xPBS (Gibco), followed by treatment with 0.25% Trypsin (Gibco) at 
37°C for 2-3 minutes to detach the cells from the tissue culture dish. The cells were 
then diluted in the SH-SY5Y culture media to inactivate the trypsin. Cells were 
pelleted by centrifugation at 300g for 3 minutes and finally resuspended in fresh 
culture media and plated.  
 
2.1.2 Generation of SH-SY5Y cell line stably overexpressing APP 
To generate an SH-SY5Y cell line that stably overexpresses APP (SH-SY5Y-APP), a 
pcDNA4 plasmid construct (Invitrogen) carrying the APP695 insert, which was 
available from the lab, was transfected into SH-SY5Y cells using the Nucleofector 
system (Amaxa) as described in section 2.2.2. This construct contains the Zeocin 
resistance gene, allowing for the selection of stable cell lines using Zeocin. Cells were 
passaged 48 hours after transfection, plated at less than 25% confluency, and 
maintained in fresh media containing 200µg/ml Zeocin (Invitrogen). Zeocin-resistant 
colonies that survived were then picked and expanded.  
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2.2 Knockdown and overexpression techniques 
2.2.1 RNA interference 
To analyse changes in gene expression under conditions of reduced AICD levels, APP 
knockdown was performed in SH-SY5Y cells. Gene knockdown was achieved using 
two different siRNA constructs (Table 2) against different regions of the APP 
transcript. The AllStars Negative Control siRNA (Qiagen) was used as a negative 
control. siRNA transfections were performed in 6-well plates at a density of 1x106 
cells per well, using 6µl RNAiMAX (Invitrogen) and 120 pmol of siRNA (Sigma). 
To achieve a higher knockdown efficiency, re-transfection was carried out on day 3 
post-transfection. Cells were harvested for gene and protein expression analysis on 
day 5 from the initial transfection. 
Table 2. APP siRNA sequences. 
siRNA 
construct 











APP si-2  
(targeting 
nucleotides 







2.2.2 Plasmid transfection 
Plasmid transfection was carried out using the Nucleofector system (Amaxa). 1.5 - 4 
million cells were suspended in 100µl of nucleofector solution (mouse NSC 
nucleofector kit, Amaxa) for transfection in a 6-well or 10cm plate format. 8-10µg of 
plasmid was added to each sample, and the mixture was subjected to nucleofection 
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using the A-023 programme for SH-SY5Y cells. Cells were harvested for gene and 
protein expression analysis 3 days post-transfection. 
 
2.3 Gene expression analysis 
2.3.1 RNA extraction 
Cells were washed twice, scraped in ice-cold PBS and centrifuged for 5 minutes at 
500g, 4°C. The obtained cell pellet was resuspended in TRIzol Reagent (Invitrogen) 
for RNA extraction, followed by purification using the RNeasy Mini kit (Qiagen) 
according to the manufacturer’s instructions. DNA contamination was removed by 
DNase treatment using the RNase-Free DNase Set (Qiagen) during the RNA 
purification step. RNA quantification was carried out using the Nanodrop 
spectrophotometer. The purified RNA was stored at -80°C.  
  
2.3.2 cDNA synthesis 
The High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) was used 
for reverse transcription. For each reaction, 1µg of RNA was reverse transcribed in a 
total volume of 20µl according to manufacturer’s instructions. Briefly, each reaction 
consists of 1x Reverse Transcriptase buffer, 1x random primers, 1x dNTP mix and 
0.25 U/µl MultiScribe Reverse Transcriptase. Reactions were incubated in a 
thermocycler (Bio-Rad) at 25°C for 10 minutes, followed by 37°C for 2 hours, with a 
final inactivation step at 85°C for 5 minutes. The synthesized cDNA samples were 
stored at -20°C. 
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2.3.3 Quantitative real-time PCR (QPCR) 
Reverse transcribed cDNA samples were diluted 5 times in nuclease-free water. 1µl 
of diluted cDNA was then added to 5µl SYBR Green Master Mix (Applied 
Biosystems), 0.4µl of a 20µM forward and reverse primer mix, and topped up to a 
total reaction volume of 10µl with nuclease-free water. Sequences of primers used are 
provided in Table 3. Reactions were carried out in technical duplicates in a 384-well 
plate, on an ABI PRISM 7900HT Real-time PCR System machine. The QPCR 
template used is reflected in Table 4. 
Table 3. List of primers for protein-coding genes used for QPCR. 



















































































Table 4. QPCR programme 
Cycles Duration of cycle Temperature (°C) 
1 10 minute 95 
30 seconds 95 
30 seconds 55 
40 
1 minute 72 
15 seconds 95 
15 seconds 55 
1 
15 seconds 95 
 
2.3.4 Microarray analysis 
Microarray analysis was carried out for SH-SY5Y cells that had APP knocked down 
by either APP siRNA1 or APP siRNA3, which are two different sets of siRNA 
targeting different regions of the APP mRNA. In addition, SH-SY5Y cells stably 
overexpressing APP were also harvested, processed and analysed on an Illumina 
microarray platform. Total RNA was extracted as described above from three 
biological replicates for each experimental treatment. Biotinylated cRNA was then 
generated from 400ng of the harvested RNA using the Illumina TotalPrep RNA 
Amplification Kit, and hybridized to HumanHT-12 v4 Expression BeadChips 
(Illumina), which contains 47231 probes against known genes. Data collection was 
carried out by scanning using an Illumina BeadStation array reader. The data was 
processed and controlled for quality using BeadStudio 3.2 (Illumina), and 
subsequently imported into GeneSpring GX 11.5 (Agilent) for analysis. Differential 
gene lists were generated based on a fold change of > 1.5. Statistical significance was 
established at p-value < 0.05 according to the unpaired Student’s t-test with the 
Benjamini-Hochberg multiple testing correction.  
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2.4 Protein expression analysis 
2.4.1 Cell lysis 
For AICD detection, cells were treated with 20mM NH4Cl for 18-24 hours 
(Vingtdeux et al., 2007) before being harvested to promote the accumulation of AICD 
for ease of detection. Cells were scraped in ice-cold PBS and centrifuged for 5 
minutes at 500g, 4°C. The cell pellet was lysed in RIPA buffer (Sigma) and Complete 
Protease Inhibitor (Roche) at 4°C for 10 minutes and subsequently cleared by 
centrifugation at 8000g, 4°C for 10 minutes. The supernatant was collected and stored 
at -80°C.  
 
2.4.2 Protein quantification  
Cell lysates were quantified using the Quick Start Bradford Protein Assay (Bio-Rad). 
BSA protein standards of 0, 1, 2, 4, 8, and 10 mg/ml were used. The protein samples 
and standards were diluted 200 times in Bradford solution and a final volume of 
200µl was dispensed in duplicate into a 96-well ELISA plate. A Tecan Sunrise 
microplate reader was used to read absorbance values at 595nm. Protein sample 
concentrations were determined from a standard curve constructed using the BSA 
standards.  
 
2.4.3 Cellular fractionation 
In order to determine the cellular localization of AICD, nuclear-cytoplasmic 
fractionation of SH-SY5Y-APP cells was performed using the NE-PER Nuclear and 
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Cytoplasmic Extraction Kit (Thermo Scientific) according to the manufacturer’s 
instructions. Briefly, after pelleting the cells, the cytoplasmic fraction was extracted 
by the addition of two different cytoplasmic extraction reagents. This was followed by 
lysis of the nuclear membrane by a nuclear extraction reagent. Both cytoplasmic and 
nuclear fractions were stored at -80°C until further use. To control for cross-
contamination of the fractions, GAPDH and hnRNP antibodies were used for western 
blotting as cytoplasmic and nuclear markers respectively. 
 
2.4.4 SDS-PAGE and western blotting 
For AICD detection, 180µg of protein was boiled at 95°C for 5 minutes with a 2x 
tricine sample buffer (Biorad) prior to loading on a 16% Tris-tricine acrylamide gel 
for better resolution of small molecular weight proteins. For APP detection, a 5x 
sample buffer was added to 50µg of protein, and an 8% or 12% Tris-glycine 
acrylamide gel used instead. Proteins were then resolved at 100V for about 1.5 hours 
and 3 hours for the Tris-glycine and Tris-tricine gel electrophoresis systems 
respectively. Subsequently, proteins were transferred to a PVDF membrane at 200mA 
for 1 hour and the electroblotted membrane was blocked with 5% (w/v) low-fat milk 
in TBST for 1 hour. The membrane was then incubated with the appropriate primary 
antibody overnight at 4°C. After washing 3 times for 10 minutes each in TBST, the 
membrane was incubated with the appropriate HRP-conjugated secondary antibody 
(Santa Cruz) at a dilution of 1:5000 for 1 hour at room temperature. Following 
another round of washing in TBST, chemiluminescence detection was performed 
using ECL Plus Western Blotting Detection Reagent (GE Healthcare). Primary 
antibodies and the dilution factors used are stated as follows: rabbit anti-APP, 1:4000 
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(A8717, Sigma); mouse anti-V5, 1:5000 (Invitrogen); mouse anti-hnRNPA2B1, 
1:1000 (Sigma); mouse anti-GAPDH, 1:1000 (Merck Millipore). 
 
2.5 Chromatin Immunoprecipitation (ChIP) 
2.5.1 Cross-linking and chromatin extract preparation  
SH-SY5Y-APP cells were treated with 20mM NH4Cl for 18-24 hours prior to 
harvesting. Cells were harvested by first rinsing them with PBS. Cross-linking was 
then carried out by incubating the cells in 2mM Dithiobis(succinimidylpropionate) 
(DSP) (Thermo Scientific) in PBS for 45 minutes, after which the cells were rinsed 
briefly in PBS, and subjected to a second cross-linking step with 1% (v/v) 
formaldehyde for 10 minutes. This two-step cross-linking method allows the 
stabilization of DNA-binding protein complexes across a larger distance and is useful 
for the immunoprecipitation of proteins that do not directly bind DNA, but act in a 
multi-protein transcriptional complex instead (Gillespie and Gudas, 2007, Nowak et 
al., 2005), which is the case for AICD. Glycine was then added to a final 
concentration of 0.2M to quench the reaction. After rinsing with PBS twice, the cells 
were collected by scraping. The nuclear fraction was isolated by washing the cells in 
cell lysis buffer (10 mM Tris pH 8, 0.25% Triton-X 100, 10 mM EDTA, 0.1 M 
NaCl), lysing the nuclei in high SDS lysis buffer (50 mM Hepes pH 7.5, 150 mM 
NaCl, 2 mM EDTA, 1% Triton X-100, 0.1% Na deoxycholate, 1% SDS), and 
washing the chromatin twice in low SDS lysis buffer (50 mM Hepes pH 7.5, 150 mM 
NaCl, 2 mM EDTA, 1% Triton X-100, 0.1% Na deoxycholate, 0.1% SDS). Complete 
Protease Inhibitor (Roche) was added to all lysis buffers. Chromatin extracts were 
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then sheared by sonication for 8 cycles (30 seconds on, 30 seconds off) using the 
Bioruptor, to obtain chromatin fragments of 500bp and below.  
 
2.5.2 Immunoprecipitation   
Antibodies used for ChIP were as follows: rabbit anti-AICD antibody (BR188), a 
generous gift from Dr. M. Goedert (Cambridge, UK); mouse anti-p53, mouse anti-
RBPJκ, normal rabbit or mouse IgG (Santa Cruz). 6µg of each antibody was 
incubated with protein G-sepharose beads for 3 hours at room temperature while the 
sonicated chromatin extract was pre-cleared with protein G-sepharose beads for 3 
hours at 4°C. The pre-cleared chromatin extract was then incubated with the antibody-
bound protein G-sepharose beads overnight at 4°C. On the next day, the beads were 
washed and the chromatin-protein-antibody complexes eluted from the beads at 68ºC 
for 30 minutes, with shaking at 1400rpm. The cross-links were reversed and protein 
was degraded using pronase (0.8mg/ml) by incubating the samples at 42°C for 2 
hours, followed by 68ºC overnight. The eluted ChIP DNA was then purified by 
phenol-chloroform extraction and resuspended in 30µl of nuclease-free water.  
 
2.5.3 Quantitative real-time PCR for ChIP 
Quantitative real-time PCR was used to determine enrichment of specific chromatin 
regions. Reactions were carried out in duplicate in a 384-well plate, on an ABI 
PRISM 7900HT Real-time PCR System machine as described in section 2.3.3. 1µl of 
ChIP DNA was used as the template for each well while 1µl of a 100x dilution of the 
input DNA (the chromatin fraction that has not undergone immunoprecipitation) was 
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used. Fold enrichment was determined by normalization of Ct values for the 
chromatin region of interest with that for input DNA, followed by a second 
normalization step with the normal IgG control. Primers used are compiled in Table 5. 
Table 5. List of primers for ChIP-QPCR. 












NME1 F: CAGCCGGAGTTCAAACCTAA 
R: CTCCTCACCTAACCCACTCC 
GPX1 F: ACAAACAGCCCTCCTCTCCT 
R: GACTCTGCCCGGTTAGAAAA 
PPM1D F: GCGTCGTCGAAGATAAACAA 
R: GTCGGAGAAGACGCTCACTC 
PTGFRN F: TGTCAGTCCGGCATTGTG 
R: ACCGCTTCCTCCTTGTCAG 
CXCL13 F: CCTGTGCAGAGATCTTGGTG 
R: AGTTCACTGCATGGGAAAGG 
DDIT4 F: TTGAGGAACAACTCGGACCT 
R: TGGGTTTCTTTGTCCGTTTC 
p53 ChIP 
MS4A4A F: ACCGTGTTCTCCTCATCTGG 
R: GTGGGAGGAGGTGTGTGAGT 
HES1 F: CGTGTCTCCTCCTCCCATT  
R: GGCCTCTATATATATCTGGGACTGC 
TMEM143 F: AGAGTTGGGAATGGATGCTG 
R: CCCTAGTTGCTGCAGAGAGC 
INVS F: GGGTCCTGTGGGATAGAAGG 
R: TAGCCGAGCCCCTCAAAAG 







SLC37A3 F: CACGCTGGGAGTTGTAGTCC 
R: CCTCTCGTCTTTTGCAGCTA 
AHCYL2 F: GGAGGAAAGGCTGAAAGGAC 
R: ACGGAACCTGTAGTGCGTTT 
 





region of NEP 
that AICD does 
not bind) 
nep ds-1  F: CCGATGCTGTGGACAAGGAGTA 
R: ACTTGTCCACCTCCTGCCGAAT 
 
2.5.4 ChIP-Seq library preparation 
ChIP-Seq was performed on an Illumina Solexa platform. ChIP-Seq libraries were 
prepared using the ChIP-Seq DNA Sample Prep Kit (Illumina), according to the 
manufacturer’s instructions. ChIP DNA was quantified using the Quant-iT PicoGreen 
dsDNA assay (Invitrogen) and 6.5ng of ChIP DNA was used as input for each sample 
library preparation. In brief, DNA was subjected to end repair and adaptor ligation, 
followed by DNA size selection by running the DNA on agarose gel and cutting out 
the area corresponding to 200-300 bp DNA fragments. The DNA was then extracted 
and purified using the Qiagen gel extraction kit, and PCR-amplified for 18 cycles. 
The quality of the ChIP-Seq library was then validated using the Bioanalyzer 2100 
(Agilent) and 5nM submitted for sequencing.  
 
2.5.5 ChIP-Seq analysis 
Short reads of 36 bp were sequenced and aligned to the hg19 Human Genome 
Assembly (GRCh37, February 2009). AICD binding sites, represented by peaks, were 
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then identified by the MACS (Model-based Analysis for ChIP-Seq) peak-calling 
algorithm. The known motif search for a known consensus sequence that AICD binds 
was performed by combining ChIP-Seq library reads from the two replicate libraries, 
and calling for peaks using MACS. All peaks were then input into the HOMER motif 
finding programme. The de novo motif search was carried out by using the top 5000 
AICD peaks as input for the MEME programme. Gene ontology (GO) analysis was 
performed using GREAT and relevant terms were ranked hypergeometrically with a 


































3.1 Next generation sequencing (NGS) approach to profiling AICD binding sites 
Our knowledge about the functions of AICD is limited, but it is thought to be linked 
to AD pathogenesis by transcriptional regulation of its target genes. The exact 
mechanisms of AICD regulation, however, is not known. Thus, furthering our 
understanding of the transcriptional functions of AICD will aid in the elucidation of 
the role of AICD in AD. Most AICD chromatin binding studies that have been 
reported involve testing the binding of the AICD transcriptional complex to a specific 
gene promoter region by means of ChIP, reporter assays or DNA electrophoretic 
mobility shift assays (EMSA). While these methods are useful for verifying the 
interaction between a transcription factor and its putative gene target, they are also 
low throughput methods that do not allow for investigations of the genome-wide 
binding patterns of AICD.  
Hence, in order to look at the global AICD binding regions on chromatin, it is 
possible to tap on NGS technology in combination with ChIP. Immunoprecipitated 
DNA from ChIP experiments can be subjected to deep DNA sequencing (ChIP-Seq) 
to identify all enriched genomic regions, which represent possible binding sites of the 
AICD transcriptional complex.  
 
3.1.1 AICD ChIP optimization 
ChIP-Seq was thus the method of choice to identify genomic regions that the AICD 
complex binds. However, before proceeding to the actual sequencing of the ChIP 
samples, optimization was essential to ensure that conditions were right for the AICD 
ChIP. ChIP, being quite an established technique, is generally not difficult to carry 
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out for many well-studied transcription factors for which ChIP-grade antibodies are 
available. However, since AICD is a relatively new entrant as a transcriptional 
modulator, optimization was necessary. This proved to be challenging for a few 
reasons. Firstly, AICD is a small protein of 6kDa that is physiologically present in 
very low levels as it has a short half-life due to rapid degradation by the insulin-
degrading enzyme. It is hence difficult to detect and immunoprecipitate. Furthermore, 
a specific antibody against AICD that would work for ChIP experiments had to be 
found.  
Other factors to be considered included the cross-linking of protein-DNA complexes 
in the cell lysate. AICD works putatively as a complex with Fe65 and Tip60, and has 
not been shown to bind DNA directly, suggesting that the interaction between AICD 
and DNA could be an indirect one mediated by another protein or protein complex. 
As such, the standard use of formaldehyde, which is more suitable for fixing direct 
protein-DNA links, may not be sufficient to cross-link AICD to chromatin. Thus, two-
step cross-linking methods had to be explored. Formaldehyde forms cross-links with a 
spacer arm length of just 2Å as compared to other cross-linkers that can extend the 
cross-links up to 16Å (Table 6). This would clearly be more suitable for stabilizing 
protein-protein interactions over longer distances, as may be the case for AICD (Zeng 
et al., 2006). Such two-step cross-linking methods have been successfully applied to 
ChIP assays (Nowak et al., 2005; van den Berg et al., 2008). In this study, DSP, 
which has a spacer arm length of 12Å was used as an additional cross-linker on top of 
formaldehyde cross-linking. 
As a benchmark of the efficiency of DNA target immunoprecipitation in the ChIP 
experiment, published gene promoter regions that AICD binds can theoretically act as 
positive controls and should be enriched in the ChIP samples. However, some of these 
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published genes were found not to be under the control of AICD in other reports 
(Hébert et al., 2006; Waldron et al., 2008). Cell type- and system-dependent 
differences may explain the variations in observed results. Hence, it was imperative 
that the right conditions were found for our system, and the right controls used to 
determine if the ChIP worked. 
Table 6. Cross-linking agents 





HCHO CH2O 37% (conc.) 2.0 Protein-DNA-RNA 
DMA C8H18Cl2N2O2 245.5 8.6 Protein-protein 
DSS C16H20N2O8 368.34 11.4 Protein-protein 
DSP C14H16N2O8S2 404.42 12.0 Protein-protein 
EGS C18H20N2O12 456.36 16.1 Protein-protein 
HCHO, formaldehyde; DMA, dimethyl adipimidate; DSS, disuccinimidyl suberate; DSP, 
dithiobis[succinimidyl proprionate]; EGS, ethylene glycolbis[succinimidyl succinate]. 
(Adapted from Zeng et al., 2006) 
 
3.1.2 Establishment of an APP overexpression system in SH-SY5Y cells 
The SH-SY5Y neuroblastoma cell line was selected in this study as it is a commonly 
used human-derived neural cell line that would be suitable for studying the 
mechanisms of AICD in the human system. Furthermore, SH-SY5Y cells express 
Fe65 and Tip60, important co-factors of AICD in the AICD transcriptional complex. 
However, a disadvantage of using the SH-SY5Y cell line is that it is a cancer cell line, 
which is not representative of a normal environment in which one would study AICD 
function as many cancer-related pathways may be consistently up-regulated. 
Differentiated SH-SY5Y cells may be an in vitro model that could be more suitable 
for studying a transcription factor that could have a role in AD. However, this was not 
feasible due to the large number of cells required for ChIP experiments.  
 44 
ChIP using an endogenous cell line is preferable since this would best reflect 
physiological conditions. However, initial attempts at AICD ChIP in endogenous SH-
SY5Y cells were not successful, perhaps due to the typically low levels of AICD. 
Thus, an in vitro system overexpressing AICD in SH-SY5Y cells had to be set up to 
overcome this problem. To this end, an SH-SY5Y cell line overexpressing APP (SH-
SY5Y-APP), and hence AICD, was generated by the stable transfection of a pcDNA4 
construct (Figure 4) carrying APP.  
Verification of APP expression levels in the stable cell line revealed APP mRNA 
levels that were about 14 times higher in the APP-transfected versus non-transfected 
cells (Figure 5A). On the protein level, both APP and AICD, which carry a C-terminal 
V5 tag, were expressed at elevated levels in the APP-transfected cells as compared to 
the endogenous cells (Figure 5B). Exogenous AICD could be differentiated from 
endogenous AICD by a difference in molecular weight due to the V5 tag at the C-
terminus of exogenous AICD. As expected, an anti-V5 antibody could only detect 
APP and its proteolytic cleavage products in the transfected cells. As indicated by the 
AICD-V5 band, exogenous AICD was expressed at a fairly similar level as 
endogenous AICD, which is advantageous for the ChIP-Seq approach as 
overexpression levels would be kept as close to physiological levels as possible to 
avoid non-specific effects that can be caused by high overexpression levels. Thicker 
bands of about 16kDa representing other APP C-terminal fragments generated by 
α/β-secretase cleavage were detected in the blot as well. This was expected as these 
longer C-terminal fragments can be recognized by the APP C-terminal antibody, carry 









Figure 4. pcDNA4 construct (Invitrogen) used to carry APP for stable transfection into SH-
SY5Y cells. The construct places the insert under the control of a CMV promoter, and 












Figure 5. Verification of APP mRNA and protein overexpression in SH-SY5Y-APP cells. 
(A) APP mRNA levels in SH-SY5Y cells stably transfected with APP and non-transfected 
(endogenous) cells were measured by QPCR. Relative fold change of APP mRNA levels was 
calculated with respect to GAPDH mRNA expression levels. The experiment was done in 
triplicate. * p<0.05 (B) Western blot analysis of the APP and AICD proteins was performed 
on SH-SY5Y cells stably transfected with APP (+) and non-transfected cells (-). Antibodies 





3.1.3 Subcellular localization of AICD  
For AICD to have a role in transcriptional control, it has to be translocated into the 
nucleus to interact with chromatin. Hence, the presence of nuclear AICD in the APP 
overexpression system had to be verified. Subcellular fractionation of SH-SY5Y-APP 
cells showed that AICD was detected in both the nuclear and cytoplasmic fractions 
(Figure 6), indicating that AICD is indeed transported into the nucleus in the SH-
SY5Y-APP stable cells, possibly for regulation of transcription. hnRNP and GAPDH 
were used as nuclear and cytoplasmic markers respectively. With the establishment of 
a cellular system stably expressing AICD that localizes to the nucleus, we could then 
move on to ChIP experiments using this cell system.  
 
Figure 6. Subcellular fractionation of SH-SY5Y-APP cells. SH-SY5Y-APP cell lysate was 
fractionated into cytoplasmic (cyto) and nuclear (nuc) fractions before western blot analysis 
was performed for AICD in both cellular fractions. Anti-hnRNP, anti-GAPDH and anti-APP 
antibodies were used to detect their respective protein levels. hnRNP and GAPDH were used 





3.1.4 AICD binds the NEP promoter region  
Before ChIP-Seq could be carried out, it was necessary to first ensure that the ChIP 
antibody and conditions allowed the immunoprecipitation of AICD and the genomic 
regions that it binds. To verify AICD immunoprecipitation of its target gene regions, 
ChIP was carried out with nuclear lysates from SH-SY5Y-APP cells using BR188, an 
anti-AICD antibody, and rabbit IgG as a control for non-specific protein-DNA 
interactions. Chromatin used for the immunoprecipitation was sheared to fragments 
below 500bp (Figure 7A). The experiment was performed in two biological replicates 
at different times and the fold enrichment in DNA was calculated by normalization 
against input DNA, which is the chromatin fraction that has not undergone 
immunoprecipitation, and rabbit IgG pull-down. 
Neprilysin, a known AICD target gene, was chosen as the positive control for 
verification of the AICD ChIP as its promoter sequence has been shown to be bound 
by AICD in a similar APP overexpression system (Belyaev et al., 2010). A NEP 
promoter region at -599bp with respect to the transcription start site was interrogated 
along with a non-promoter control region downstream of the NEP transcription start 
site that is not expected to interact with AICD. An average enrichment of about 25-
fold was observed for the promoter region as compared to about 5-fold or less for the 
non-promoter control region (Figure 7B), indicating that the NEP promoter region is 
enriched in the AICD ChIP DNA, and that AICD binds to the NEP promoter. With 
confirmation that the AICD ChIP was successful, DNA for the two ChIP replicates 
were prepared as separate libraries and submitted for sequencing for the identification 





Figure 7. Enrichment of NEP promoter region in AICD ChIP. (A) ChIP was carried out 
using SH-SY5Y-APP chromatin that has been sheared to fragments below 500 bp. (B) 
BR188, an anti-AICD antibody, and rabbit IgG (control antibody) was used to 
immunoprecipitate chromatin. This was performed in biological duplicates (AICD ChIP 1 and 
2). Enrichment of the NEP promoter and a downstream, non-promoter negative control region 
was measured by QPCR, and normalized against input DNA and rabbit IgG.    
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3.2 Genome-wide transcriptional binding profile of AICD 
ChIP-Seq was performed to map a global transcriptional binding profile of AICD. 
This was done in biological duplicates with the entire experiment, including 
chromatin harvesting, ChIP, and the sequencing for each replicate done months apart. 
Two ChIP-Seq DNA libraries were prepared and quality control checks of the DNA 
were run using the Agilent Bioanalyzer 2100. The number of mappable reads 
sequenced from each ChIP library is summarized in Table 7. The reads were aligned 
against the hg19 Human Genome Assembly (GRCh37, February 2009) and peak 
calling was performed using MACS (Model-based Analysis for ChIP-Seq). MACS is 
one of many algorithmic approaches that identifies, based on the density of aligned 
reads at genomic locations, ‘peaks’ at genomic regions where sequenced reads are 
enriched at, representing likely binding sites of the protein of interest. Peak calling by 
MACS generated 21,569 and 17,917 AICD binding sites for the respective replicate 
ChIP-Seq libraries (Table 7).  
To determine how well the two ChIP-Seq replicates were correlated, AICD binding 
sites in both libraries were compared (Figure 8). 10,239 AICD binding sites were 
identified in both ChIP-Seq libraries. It is expected that the overlapping binding sites 
do not make up a high percentage of the total number of binding sites in each library 
since such high variability is typical in ChIP-Seq experiments. However, a large 
absolute number of AICD binding sites are represented in both libraries, indicating 





Table 7. Number of AICD ChIP-Seq mapped reads and binding sites.  
 
 AICD ChIP-Seq 1 AICD ChIP-Seq 2 
No. of mapped reads 14,516,262 14,028,330 
No. of binding sites 21,569 17,917 
 
Sequenced reads were aligned against the hg19 Human Genome Assembly and peak calling 
was performed using the MACS programme. 
 
 
Figure 8. Overlap of AICD binding sites identified in two replicate ChIP-Seq libraries. 
Genomic regions identified as AICD binding sites in the two ChIP-Seq libraries were 
correlated and 10,239 binding sites were identified in both libraries.  
 
The AICD binding sites were then classified according to the functional genomic 
elements (promoter, 5’ UTR, exon, intron, intergenic, 3’ UTR, or the transcription 
termination site [TTS]) they were located at, with respect to the gene that is most 
proximal to the binding site. This gives us an indication of the distribution of AICD 
binding sites at the different types of genomic elements (Figure 9). The percentage 
distribution of binding sites across different genomic elements is similar for both 
ChIP-Seq replicates. About 20% of the identified binding sites were annotated to gene 
promoter regions, with promoter regions defined as 1kb upstream and downstream of 
the transcription start site (TSS). As expected, a large percentage of binding sites 
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overlapped with intergenic (~35%) or intronic regions (~30%), which is rather typical 





Figure 9. Distribution of AICD binding sites across functional genomic elements. AICD 
peaks called by the MACS programme, which represent AICD binding sites, were classified 
according to the types genomic elements they localized to. This was performed separately for 
the two ChIP-Seq replicates. Promoter binding sites were defined as binding sites found 
within 1kb upstream and downstream of the transcription start site. 
 
A scan for some of the known target genes that AICD regulates revealed AICD 
binding sites at promoter regions of these genes, including BACE1, APP, GSK3β and 
EGFR, for both ChIP-Seq replicates (Figure 10). These binding sites can be viewed as 
peaks located with reference to RefSeq genes. The peak profiles show details like 
peak heights and how the sequenced reads are distributed along the genome. The 
observation of AICD binding sites at promoters of known targets of AICD 
transcriptional regulation suggests that the ChIP-Seq experiment was able to pick up 

















Figure 10. AICD binding sites at promoters of known AICD transcriptional targets. 
Sequenced reads were mapped against the hg19 human reference genome and read densities 
reflected as peak profiles. Peak calling was performed using MACS (Model-based Analysis 
for ChIP-Seq) and identified peaks are represented as solid bars spanning the peak width on 
the Integrative Genomics Viewer (IGV). The ChIP-Seq data revealed AICD binding sites 
near the promoters of AICD targets like (A) BACE1, (B) APP, (C) GSK3β and (D) EGFR in 
both ChIP-Seq replicates (ChIP-Seq 1 and 2). 
 
3.2.1 AICD peaks coincide with active and repressive epigenetic marks 
Epigenetic modifications are crucial to the regulation of genomic function by altering 
global chromatin environments to allow for gene expression control. One way by 
which the epigenome exercises genomic control is via histone modifications like 
lysine methylation and acetylation, which are associated with different functional 
states at various genomic locations. With the advent of techniques like ChIP-on-chip 
and ChIP-Seq, studies mapping genome-wide epigenetic landscapes are possible. The 
AICD peaks elucidated in this study can thus be mapped to available epigenetic data 
to determine if the AICD binding sites are associated with any specific epigenetic 
marks. Since different epigenetic marks signify distinctive chromatin states, this 
would help in the understanding of AICD binding patterns and its control over 
transcription.  
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The H3K27ac and its opposing H3K27me3 marks are correlated with gene activation 
(Creyghton et al., 2010; Rada-Iglesias et al., 2011) and repression (Boyer et al., 2006; 
Lee et al., 2006; Roh et al., 2006) respectively. The AICD ChIP-Seq peaks were 
mapped to genomic locations in post-mortem non-AD human brain tissues from the 
hippocampus or the cingulate gyrus that were enriched in the H3K27ac or H3K27me3 
marks (available from NIH Roadmap Epigenomics Mapping Consortium, 
GSE17312). The hippocampus and the cingulate gyrus are brain regions known to 
undergo atrophy in AD and were thus selected as for their relevance to AD (Jones et 
al., 2006; Kerchner et al., 2012). Results are presented in the form of a plot which 
shows the presence of any corresponding H3K27ac or H3K27me3 marks in the 
respective brain samples at the AICD binding locations (Figure 11). Both active 
H3K27ac and repressive H3K27me3 marks in the hippocampus and the cingulate 
gyrus were found to be present at AICD binding sites in SH-SY5Y-APP cells, 
although a larger number of AICD peaks coincided with the active mark. 
Although the epigenomic profiles of the SH-SY5Y-APP cells and the two brain 
regions are ultimately different due to variations in in vivo and in vitro systems, this 
comparison allows for the prediction of the association of AICD binding sites with 
active or repressive marks. Hence, the observation that AICD was bound at both 
transcriptionally activated and repressed genomic locations suggests that AICD is 
involved in transcriptional regulation and in different situations, could have both 




Figure 11. Heatmap of active or repressive histone marks around AICD peaks. Genomic 
locations where AICD binds in the SH-SY5Y-APP cells were correlated to active H3K27ac 
and repressive H3K27me3 marks found at the same locations in hippocampal and cingulate 
gyrus human brain tissues. Both active H3K27ac and repressive H3K27me3 marks were 
found in the vicinity of AICD peaks. 
 
3.2.2 Motif analysis 
The AICD complex, as a transcriptional regulatory complex, might recognize and 
bind a consensus sequence in chromatin to regulate the expression of specific genes. 
To identify such a consensus sequence, motif analysis was performed using a known 
motif finding and a de novo motif finding strategy. A known motif search allows the 
detection of consensus sequences from known motifs in a database at the identified 
AICD binding sites. The binding sites will be scanned for consensus sequences that 
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have already been discovered and deposited in the database, and the most commonly 
occurring consensus sequences will be reported. On the other hand, a de novo motif 
search identifies the most commonly occurring consensus sequence at the AICD 
binding sites regardless of whether the motif is known.  
For known motif finding, reads from both ChIP-Seq libraries were combined for 
greater sequencing depth. These combined reads gave a total of 34,297 peaks with the 
MACS peak calling algorithm. These AICD peaks were used as input for the 
HOMER motif finding programme and motifs were identified and ranked according 
to their p-values. Unexpectedly, the motif search did not yield a single motif with a 
significant p-value as is typical of other transcription factors. Instead, a number of 
motifs with significant p-values were identified and listed in Table 8. The top motif 
corresponds to the p53 motif and has a p-value of 1e-75. Other motifs corresponding to 
that of MyoD, ATOH1, SCL, NF1, TCF12, ETS, p63, ELF1 and LHX3 were found in 
the top ten motifs, with p-values ranging from 1e-69 to 1e-23.   
The de novo search strategy involved using the top 5000 AICD binding sites (ranked 
according to p-value) as input for the MEME programme, which is another motif 
search strategy optimized for the discovery of previously unknown motifs. The top de 
novo motif discovered is shown in Figure 12, with its reverse complement, and has a 
highly significant p-value of 4.8e-332. Most of the other highly ranked motifs found 
were either similar to the top motif or consisted of low complexity motifs or simple 
repeats. Since a de novo search strategy was used, a further literature search was 
necessary to determine if the identified consensus sequence is relevant to any 
transcription factors or if it is similar to any reported motifs. Indeed, the RBPJκ motif 
was found to be embedded in the discovered de novo motif.  
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Table 8. Known motifs enriched in AICD binding sites. 
 
Combined reads from the two ChIP-Seq libraries were input into HOMER for known motif 







Figure 12. De novo motif (and its reverse complement) most enriched in AICD binding 
sites. The top 5000 AICD binding sites were used as input for a de novo motif search by the 
MEME programme. The top motif that was identified is shown, with a highly significant p-
value of 4.8e-332. The red boxes indicate an embedded RBPJκ motif. 
 
3.2.3 AICD shares common genomic binding sites with p53 and RBPJκ  
Due to the number of significant motifs identified, the AICD complex could possess 
the ability to recognize and bind to a number of different motifs. It is necessary then, 
for the involvement of a sequence-specific component that can mediate the binding of 
the AICD complex to different motifs. Hence, AICD could interact with different 
partner transcription factors and target gene regulatory regions that carry motifs which 
the partner transcription factor recognizes. In this way, AICD regulates specific sets 
of genes according to the transcription factor it interacts with. In order to test this 
hypothesis, a ChIP assay using antibodies against the associated partner transcription 
factors can be performed and the enrichment in AICD binding sites measured. If 
AICD indeed interacts with other transcription factors to target common gene 
regulatory regions, enrichment in these regions would be observed in both the AICD 




To decide which transcription factors are more likely to act in transcription with 
AICD, a closer look at the motif search results had to be taken. Notably, the 
consensus sequences for some of the motifs that came up were very similar. One of 
these sequences, which appear in the MyoD, ATOH1, SCL, and TCF12 motifs, is the 
‘CAGCTG’ sequence, which is reminiscent of a ‘CANNTG’ E-box motif. Similarly, 
the p53 and p63 motifs match almost identically. This is likely due to HOMER 
matching a particular consensus sequence to different transcription factors that target 
similar sequences, as in the E-box motif. In order to identify the relevant transcription 
factors that could interact with AICD, their expression in the SH-SY5Y-APP cells had 
to be verified. This information was obtained from microarray expression data for the 
SH-SY5Y-APP cells, which will be described later. mRNA expression levels were 
obtained as a rough percentile value from a ranking of genes according to their signal 
intensity (Table 9). Transcription factors with expression levels above the 50th 
percentile in the SH-SY5Y-APP cells (highlighted in grey) were considered more 
likely to be relevant as transcription partners of AICD.  
The top known motif, p53, was found in 658 AICD binding sites across the genome, 
suggesting that p53 co-binds and may co-regulate these common binding sites 
together with the AICD complex. This was verified by testing for the enrichment of a 
handful of AICD binding sites in chromatin immunoprecipitated by p53. A ChIP 
assay with a p53 antibody was performed in triplicate using SH-SY5Y-APP cell 
lysate, along with a normal IgG pull-down as negative control. Regions of interest 
were probed for enrichment in the p53 pull-down by means of QPCR. Fold 
enrichment was calculated with normalization to input DNA and normal IgG, and 
results were expressed as fold enrichment at the AICD binding sites relative to that at 
a non-binding region downstream of NEP (nep ds-1). As a positive control for the p53 
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ChIP, the promoter region of p21, a well-known target gene of p53 regulation, was 
probed and verified to be enriched to almost 35-fold relative to the negative binding 
region (Figure 13A). Eight AICD binding sites carrying the p53 motif was tested for 
enrichment in the p53 ChIP and most of these sites were observed to be enriched, 
although not all to a very large extent (Figure 13B).  
Similar experiments were performed with an RBPJκ antibody instead to test the 
hypothesis that RBPJκ also binds common regulatory regions on chromatin with 
AICD. 159 AICD binding sites, out of the top 5000 binding sites that were used for de 
novo motif finding, were found to contain the RBPJκ motif. Of these sites, seven were 
tested for enrichment in the RBPJκ ChIP, which was similarly proven to have worked 
as there was a 6-fold enrichment in the promoter region of its known target gene, 
HES1 (Figure 14A). The AICD binding sites were again enriched in the RBPJκ pull-
down, but not by exceptionally large fold changes (Figure 14B). Statistical 
significance was also more difficult to achieve for RBPJκ, perhaps due to the lower 
efficiency of the RBPJκ antibody used.  
Since p53 and RBPJκ have been shown to bind different sets of AICD binding sites, it 
is possible that the AICD complex interacts with either p53 or RBPJκ to localize to 
specific subsets of genomic locations in a p53- or RBPJκ-dependent manner. Effects 
of this transcriptional regulation and subsequent downstream changes in cellular 





Table 9. Absolute mRNA expression levels of potential partner transcription 

















Absolute expression levels of transcription factors identified in the motif searches were 
determined using microarray data. Expression levels are expressed as a percentile value 
according to a ranking of gene signal intensities. An expression level above the 50th percentile 
(in grey) was interpreted as more likely to act as partner transcription factors of AICD. 
 
















Figure 13. p53 ChIP and verification of its common binding sites with AICD. ChIP was 
performed using chromatin isolated from SH-SY5Y-APP cells. A p53 antibody and normal 
IgG was used to immunoprecipitate chromatin. Enrichment was measured by QPCR for (A) 
p21, a p53 target gene, which was used as a positive control for the p53 ChIP, and for (B) 
eight AICD binding sites carrying the p53 motif. Fold enrichment was calculated by 
normalization against input DNA and normal IgG, and results were plotted as the fold 
enrichment relative to that at a negative control region that AICD does not bind (nep ds-1). 





Figure 14. RBPJκ  ChIP and verification of its common binding sites with AICD. ChIP 
was performed using chromatin isolated from SH-SY5Y-APP cells. An RBPJκ antibody and 
normal IgG was used to immunoprecipitate chromatin. Enrichment was measured by QPCR 
for (A) HES1, an RBPJκ target gene, which was used as a positive control for the RBPJκ 
ChIP, and for (B) seven AICD binding sites carrying the RBPJκ motif. Fold enrichment was 
calculated by normalization against input DNA and normal IgG, and results were plotted as 
the fold enrichment relative to that at a negative control region that AICD does not bind (nep 
ds-1). Experiments were done in triplicate and statistical significance represented as * p<0.05. 
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3.3 Gene expression profile of APP overexpression and knockdown cells 
Even though the ChIP-Seq technique is extremely useful for determining the binding 
patterns of AICD across the genome, it alone is unable to provide more information 
about the genes that are not only bound, but also functionally regulated by AICD. As 
such, gene expression profiling can be a good method to complement the AICD 
binding profile as elucidated by ChIP-Seq. To this end, microarray analysis was 
carried out for the SH-SY5Y-APP stable cell line and APP knockdown SH-SY5Y 
cells. Two different siRNAs (si-1 and si-2) targeting APP were separately transfected 
into SH-SY5Y cells. To eliminate off-target siRNA knockdown effects, the 
transfection of a non-target siRNA (si-NT) was performed as a negative control. For a 
higher knockdown efficiency, cells were transfected a second time with the respective 
siRNAs three days after the initial transfection. Cells were ultimately harvested 
another two days after the second transfection, following which the knockdown 
efficiency was assessed on both the mRNA and protein levels. Both si-1 and si-2 
achieved a knockdown efficiency of about 70% as compared to the si-NT control 
(Figure 15A). Protein levels of both APP and AICD were reduced as well (Figure 
15B). Isolated mRNA from the SH-SY5Y-APP and APP knockdown cells were then 
subjected to microarray profiling, which would reveal differentially expressed genes 
under conditions that allow for AICD over- and under-expression.  
The number of differentially expressed genes with the overexpression and knockdown 
of APP is shown in Table 10. Genes were selected based on a fold change cut-off of 
1.5 relative to control and had a false discovery rate (FDR) < 0.05. In summary, 3798 
genes were differentially expressed when APP was overexpressed while 1725 and 






Figure 15. APP/AICD knockdown in SH-SY5Y cells for expression profiling. 2 different 
siRNAs targeting APP, si-1 and si-2, were individually transfected into SH-SY5Y cells. (A) 
mRNA expression levels of APP upon si-1 and si-2 knockdown relative to a non-target 
siRNA control (si-NT) was measured by QPCR. Expression of GAPDH mRNA was used as 
an internal control. (B) Western blot analysis of the APP and AICD proteins was performed 
using an antibody against the C-terminus of APP. GAPDH protein levels were detected by an 






Table 10. Number of differentially expressed genes with APP overexpression and 
knockdown in SH-SY5Y cells. 





Up-regulated 1759 880 1046 
Down-regulated 2039 845 1521 
Total differentially 
expressed 3798 1725 2567 
 
Microarray analysis was performed for the SH-SY5Y-APP cells and SH-SY5Y cells 
subjected to APP knockdown with two different siRNAs. A fold change cut-off of 1.5 relative 
to control was used and statistical significance was established at FDR < 0.05. 
 
 
respectively. The proportion of up-regulated and down-regulated genes in each list 
were roughly equal, with the exception of the si-2 knockdown, which had 1.5 times 
more down-regulated than up-regulated genes. Since si-1 and si-2 essentially target 
the same gene for knockdown and are expected to result in similar changes, their 
respective differential gene lists were compared. 736 genes were found to be 
regulated in the same direction in both APP knockdown conditions (Figure 16). This 
does not represent a large overlap of the two lists and is perhaps due to off-target and 
siRNA-specific effects common in siRNA knockdown experiments. Hence, to 
increase the stringency of the dataset used, the 736 overlapping genes were used for 
subsequent analyses.  
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Figure 16. Overlap of differentially expressed genes in si-1 and si-2 knockdown of APP. 
Genes identified by microarray analysis to be differentially regulated in SH-SY5Y cells with 
APP knocked down by either si-1 or si-2 were overlapped. 736 genes were found to be 
differentially regulated in the same direction in both si-1 and si-2 knockdown samples.  
 
Validation of 11 genes that were differentially up- or down-regulated upon APP 
overexpression was performed by QPCR on additional biological replicates that were 
generated (Figure 17). These genes were selected from a range of microarray 
expression fold changes. As expected, the QPCR fold changes correlated with that 
observed in the microarray data. Similarly, validation was done for genes that were 
differentially up- or down-regulated by APP si-1 and si-2 knockdown (Figure 18). A 
similar trend in relative expression levels was observed for QPCR data as compared 





Figure 17. QPCR validation of differentially regulated genes from microarray analysis 
(APP overexpression). Genes which were (A) up-regulated or (B) down-regulated to varying 
degrees upon APP overexpression were selected from microarray data to be validated. QPCR 
fold changes were plotted in comparison to microarray fold changes. Experiments were done 





Figure 18. QPCR validation of differentially regulated genes from microarray analysis 
(APP knockdown). Genes which were (A) up-regulated or (B) down-regulated by both APP 
si-1 and si-2 knockdown were selected from microarray data to be validated. QPCR fold 
changes were plotted in comparison to microarray fold changes. Experiments were done in 
triplicate and statistical significance represented as * p<0.05. 
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3.4 Cellular functions relevant to genes putatively bound and regulated by AICD  
The expression profiles of APP overexpression and knockdown in SH-SY5Y cells 
allow the identification of genes that are regulated directly by AICD or indirectly by 
additional downstream signals. To tease the two effects apart, comparison of the gene 
expression profile and the AICD binding profile was carried out to identify genes 
directly bound and regulated by AICD. Genes within a 20kb distance from AICD 
peaks that were also present in the overexpression or knockdown expression dataset 
represent genes that are likely to be directly targeted by AICD in transcriptional 
control. In order to elucidate the biological functions that AICD regulates via its gene 
targets, GO analysis was performed for up- and down-regulated genes separately, 
revealing a multitude of biological processes and pathways involved. GO terms 
identified were grouped according to the microarray dataset used and the top four to 
five terms in the ‘molecular function’, ‘biological process’ and ‘pathway’ categories 
are shown (Table 11). The number of genes that are bound and regulated in each 
group is reflected as well. 
Some of the revealed terms like ‘cell cycle’, ‘p53 pathway’ and ‘apoptosis signaling’ 
are not unexpected. Changes in cell cycle regulation and the activation of apoptotic 
signals have previously been linked to neuronal death in AD. Of the apoptotic signals, 
p53 has been one of the most well-studied, and it is unsurprising that the p53 pathway 
came up since it is also known to be transcriptionally up-regulated by AICD (Alves 
da Costa et al., 2006). Other biological processes, like ‘diabetes pathways’ did not 
seem to be relevant at first glance. However, there have been links between the 
development of diabetes and AD, making this an interesting area to look into. The 
cellular functions differentially regulated upon changes in AICD levels will be 
discussed further in the next section. However, a number of genes that are both bound 
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and regulated by AICD, and that are relevant to some of the identified GO terms are 
summarized below. 
Table 11. Enriched GO terms for genes up- or down-regulated in APP overexpression 
(OE) or knockdown (KD) conditions, and present within 20kb of an AICD binding site.   




syntaxin binding,  
phosphatidylinositol-3-
phosphate binding,  
protein kinase regulator 
activity,  
kinase inhibitor activity, 
phosphatase activity  
 
regulation of skeletal 
muscle tissue 
development,  
synaptic vesicle transport,  
cell-cell signaling,  
receptor clustering,  
synaptic transmission  
Wnt,  
Reelin signaling pathway, 
Recycling pathway of L1, 






kinase regulator activity, 




containing groups,  
protein serine/threonine 
kinase inhibitor activity,  
DNA-directed DNA 
polymerase activity  
 
cell cycle phase,  
mitotic cell cycle,  
regulation of cell cycle,  
M phase,  
DNA metabolic process 
Polo-like kinase signaling 
events in the cell cycle,  
FOXM1 transcription 
factor network,  
Activation of the pre-




O-acyltransferase activity,  
apolipoprotein E binding, 





phosphatase activity  
positive regulation of 
nuclear-transcribed mRNA 
poly(A) tail shortening,  
pancreas development,  
generation of neurons,  
ubiquitin-dependent 
protein catabolic process,  
modification-dependent 
protein catabolic process 
Diabetes pathways,   
Sema4D mediated 
inhibition of cell 
attachment and migration, 
p53 pathway,  
L13a-mediated 
translational silencing of 










oxide reductase activity 
tRNA (guanine-N7-)-
methyltransferase activity 
nucleic acid metabolic 
process,  
cellular response to stress,  
regulation of cell growth,  
interphase of mitotic cell 
cycle,  
regulation of transcription 
involved in G1/S phase of 
mitotic cell cycle,  
response to DNA damage 
stimulus,  
DNA repair  
Genes involved in Cell 
Cycle, Mitotic,  
Pyrimidine metabolism,  
Base excision repair,  
Genes involved in S 
Phase,  





GO analysis was performed using GREAT and the top 4-5 terms based on hypergeometric 
rank and a significance level of binomial FDR q-value < 0.05 are shown. 
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A number of cell cycle regulation genes were both regulated and bound by AICD 
(Table 12, Figure 19). These include cyclins E1, B1 and B2 which were down-
regulated in APP knockdown cells and the cyclin-dependent kinase CDK6 which was 
up-regulated in APP overexpression cells. CDK inhibitor levels, in general, were 
similarly diminished with APP knockdown and increased with APP overexpression. 
Such trends in the expression changes indicate an up-regulation of genes that promote 
cell cycle progression. Increase in CDK inhibitor levels represent a rise in genes that 
arrest the cell cycle, perhaps in response to the aberrant cell cycle re-entry signals. 
Some contradicting changes were observed, like the increase in expression of 
CDKN1A upon APP knockdown and the drop in CDC25B levels when APP was 
overexpressed. These may be due to compensatory mechanisms and feedback loops 
that confound the actual influence of AICD.  
DNA repair genes bound by AICD, like PCNA, FANCD2 and FOXM1, were 
consistently down-regulated upon APP overexpression (Table 13, Figure 20), 
suggesting that regulation by AICD could disrupt these genes and compromise DNA 
repair mechanisms. Many p53 pathway-related genes were up-regulated with APP 
overexpression (Table 14). For example, p53 targets like BBC3, GADD45A and 
GDF15, and the p53 activator ATF3, were found to be expressed at increased levels 
although the expression of p53 itself was unexpectedly reduced by 2-fold instead. 
However, the general trend indicates an overall activation of the p53 pathway. 
Apoptosis-related genes like BCL2 and HSPA5, which have suppressive roles in 
apoptosis, were down-regulated with APP overexpression (Table 14) and found to be 
bound by AICD (Figure 21). Thus, apoptotic signals could be enhanced to some 
extent, which is consistent with the up-regulated p53 pathway. However, other pro-
apoptotic genes like RIPK1, MAPK9 and CASP7 were down-regulated at the same 
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time in the APP overexpression dataset, suggesting a suppression of apoptosis instead. 
It is likely that different intrinsic and extrinsic apoptotic pathways are involved and 
looking at apoptosis as a whole is insufficient to explain the changes observed. 
Genes that are related to the diabetes pathway are summarized in Table 15. IGFBP-4, 
-5 and -6, which are insulin-like growth factor (IGF) binding proteins that can 
modulate the signaling potential of IGFs, were down-regulated upon APP 
overexpression. Additionally, AICD binding sites were also present within 20kb of 
their genes (Figure 22). This indicates a possibility that AICD could be linked to 














Table 12. Genes bound by AICD and regulated by APP knockdown or overexpression 









CCNE1 1.9x↓ Cyclin E1; forms cyclin/cdk complex with CDK2, required 
for G1/S transition 
CCNB1 1.8x↓ Cyclin B1; complexes with CDK1 to form cyclin/cdk 
complex important for mitosis, accumulates during G2/M 
phase 
CCNB2 2.1x↓ Cyclin B2; crucial for G2/M phase of cell control cycle 
CDKN1A 2.6x↑ CDK inhibitor 1A (p21, Cip1); inhibits cyclin/CDK2 or 
/CDK4 complexes, important in cell cycle G1 phase, 
negative regulator of cell proliferation 
CDKN1C 2.3x↓ CDK inhibitor 1C (p57, Kip2); inhibits several cyclin/CDK 
complexes involved in G1 phase, negative regulator of cell 
proliferation 
CDKN2C 1.9x↓ CDK inhibitor 2C (p18); inhibits CDK4 or CDK6, inhibits 
cell cycle G1 progression 
AURKB 2.4x↓ Aurora kinase B; serine/threonine protein kinase component 
of the chromosomal passenger complex which is a key 











CDK6 1.6x↑ Cyclin-dependent kinase 6; important for G1 progression 
and G1/S transition 
CDC25B 1.5x↓ Cell division cycle 25B; required for G2/M phase of cell 
cycle progression  
CDKN1A 2.8x↑ CDK inhibitor 1A (p21, Cip1); inhibits cyclin/CDK2 or 
/CDK4 complexes, important in cell cycle G1 phase, 
negative regulator of cell proliferation 
CDKN1C 1.7x↑ CDK inhibitor 1C (p57, Kip2); inhibits several 
cyclin/CDK complexes involved in G1 phase, negative 
regulator of cell proliferation 
RB1 1.7x↓ Retinoblastoma 1; tumour suppressor, regulates entry 
into cell division, promotes G0/G1 transition when 
phosphorylated, promotes cell cycle arrest when under-
phosphorylated 
FBXO5 1.7x↓ F-box protein 5; Mitotic regulator that inhibits the 







































Figure 19. AICD binding sites associated with cell cycle control genes. ChIP-Seq data 
revealed AICD peaks that represent binding sites associated with cell cycle control genes 
including CCNE1, CCNB1, CCNB2, CDKN1A, CDKN1C, CDKN2C, AURKB, CDK6, 






Table 13. Genes bound by AICD and regulated by APP overexpression that are relevant 









PCNA 1.9x↓ Proliferating cell nuclear antigen; Processivity factor of 
DNA polymerase delta, involved in DNA synthesis and 
repair 
FANCD2 1.7x↓ Fanconi anemia, complementation group D2; required 
for maintenance of chromosomal stability, involved in 
DNA double-strand break repair 
DTL 2.2x↓ Denticleless E3 ubiquitin protein ligase homolog; DCX 
E3 ubiquitin protein ligase adapter, implicated in cell 
cycle control and DNA damage response 
APITD1 1.8x↓ Apoptosis-inducing, TAF9-like domain 1; DNA-binding 
component of the Fanconi anemia core complex, 
involved in DNA damage repair and genome 
maintenance 
FOXM1 1.8x↓ Forkhead box M1; Transcription factor involved in DNA 




















Figure 20. AICD binding sites associated with DNA repair genes. ChIP-Seq data revealed 
AICD peaks that represent binding sites associated with DNA repair genes including PCNA, 







Table 14. Genes bound by AICD and regulated by APP overexpression that are relevant 









TP53 2.0x↓ Tumour protein p53; induces growth arrest or apoptosis, 
tumour suppressor 
ATF3 3.4x↑ Activating transcription factor 3; binds the cAMP 
response element (CRE), involved in cellular stress 
response, activates p53, may induce cell death via the 
intrinsic death pathway  
BBC3 1.7x↑ BCL2 binding component 3; regulated by p53 and 
mediates p53-dependent and p53-independent apoptosis 
GADD45A 2.2x↑ Growth arrest and DNA-damage-inducible, alpha; p53- 
and BRCA1-regulated stress-inducible gene, plays 
important roles in cell cycle checkpoint control, DNA 
repair and signal transduction 
GDF15 
 
19.7x↑ Growth differentiation factor 15; member of the TGF-
beta superfamily, direct transcriptional target of p53, 
downstream mediator of DNA damage signaling  
BCL2 3.5x↓ B-cell lymphoma 2; suppresses apoptosis in various cell 
types including neural cells, inhibits caspase activity 
HSPA5 1.7x↓ Heat shock 70kDa protein 5 (glucose-regulated protein, 
78kDa); involved in protection against ER stress-induced 
apoptosis 
RIPK1 1.8x↓ Receptor (TNFRSF)-interacting serine-threonine kinase 
1; transduces cell death signals upon activation by death 
receptors 
MAPK9 1.6x↓ Mitogen-activated protein kinase 9; implicated in various 
cellular processes like programmed cell death, 
proliferation, differentiation and development 




































Figure 21. AICD binding sites associated with p53 and apoptosis signaling pathway 
genes. ChIP-Seq data revealed AICD peaks that represent binding sites associated with the 
p53 and apoptosis signaling pathway genes including TP53, ATF3, BBC3, GADD45A, 
GDF15, BCL2, HSPA5, RIPK1, MAPK9 and CASP7. 
 
 
Table 15. Genes bound by AICD and regulated by APP overexpression that are relevant 









ATF3 3.4x↑ Activating transcription factor 3; cAMP responsive 
element-binding protein induced by various signals, 




1.6x↑ Golgi SNAP receptor complex member 2; involved in 
protein transport from the cis/medial-Golgi to the trans-
Golgi network 
ASNS 1.6x↑ Asparagine synthetase; involved in the synthesis of 
asparagine 
WIPI1 3.7x↑ WD repeat domain, phosphoinositide interacting 1; 
functions in many biological processes, binds 
phosphatidylinositol-3-phosphate for recruitment to 
membranes, may play a role in autophagy 
IGFBP4 2.8x↓ Insulin-like growth factor (IGF) -binding protein 4; binds 
IGFs and alters their interaction with cell surface 
receptors  
IGFBP5 2.2x↓ IGF-binding protein 5; binds IGFs and alters their 
interaction with cell surface receptors 
IGFBP6 1.8x↓ IGF-binding protein 6; binds IGFs and alters their 





























Figure 22. AICD binding sites associated with diabetes pathway genes. ChIP-Seq data 
revealed AICD peaks that represent binding sites associated with the diabetes pathway genes 









3.5 Comparison of in vitro APP overexpression and human AD brain gene 
expression profiles   
The in vitro APP overexpression system provided conditions that allowed for the 
increased expression of AICD. Since we have hypothesized that AICD could be 
responsible for many changes seen in AD pathogenesis, it would be interesting to 
compare the gene expression profile relevant to increased AICD levels to the 
expression profile in human AD brain tissue. The comparison would reflect the extent 
to which AICD can explain the changes in gene expression in actual AD conditions, 
taking into account the limitations of comparing in vitro and in vivo systems. It would 
also be useful to narrow down the list of differentially regulated genes in our system 
to the most pertinent genes that are changing in human AD conditions. Hence, the 
expression data for the SH-SY5Y-APP cells was compared to the gene expression 
profile of AD patient neocortex tissues (Tan et al., 2010). This study investigated the 
gene expression changes in the temporal cortex of 12 autopsied AD patients, relative 
to 8 elderly controls. 
Genes that were differentially regulated in the SH-SY5Y-APP cells (previously 
verified for AICD up-regulation) were categorized into up- and down-regulated genes 
and compared to the corresponding groups of genes regulated in the AD patients. 21 
genes were found to be up-regulated in both the APP overexpression cells and in AD 
brains while 100 genes were found to be overlapping for the down-regulated genes 
(Figure 23). In addition, 27 genes were found to be down-regulated in the 
overexpression cell line but up-regulated in AD brains while 68 genes were up-
regulated in the overexpression cell line but down-regulated in AD brains.  
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The fact that the proportions of overlapping genes were not large, and that some genes 
were found to be regulated in opposite directions was not entirely surprising. Firstly, 
in vitro and in vivo samples are known to be rather different and secondly, the sole 
overexpression of APP is understandably an insufficient representation of such a 
multifactorial disease as AD. However, the comparison between the two datasets may 




Figure 23. Number of genes differentially regulated in both APP overexpression cells 
and human AD brain tissue. (A) Up-regulated and (B) down-regulated genes in SH-SY5Y-
APP cells and human AD brain samples were overlapped. A cut-off of fold change > 1.5 and 
p < 0.05 was used for the AD brain data.   
 
In order to identify cellular functions and pathways represented by the regulated 
genes, GO analysis was performed for the overlapping genes that were up- or down-
regulated in both expression profiles and the top GO terms were summarized in Table 
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16. The up-regulated genes were enriched in ‘DNA bending activity’, ‘anti-apoptosis’ 
and ‘PI3K signaling’ while down-regulated genes were involved mainly in 
‘cytoskeleton organization’ and ‘neurotransmitter release cycle’.  
Additionally, GREAT GO analysis compared the down-regulated genes with the 
Molecular Signatures Database (MSigDB) and identified a gene set representing 
down-regulated genes in AD subjects (Blalock et al., 2004) that correlated well with 
our data (p = 1.7107e-14 and binomial FDR q-value < 0.05). The gene set was based 
on microarray data from 22 AD subjects and 40 genes from our down-regulated gene 
list were also found to exhibit lower expression levels in the MSigDB gene set. This 
indicates that at least some of the genes differentially regulated in the APP 
overexpression cells reflect actual gene alterations in vivo, and could be involved in 
molecular mechanisms that contribute to AD development. 
 
Table 16. Enriched GO terms for overlapping genes in the APP overexpression cell line 
(APP-OE) and human AD brain (AD). 
Category Molecular function Biological process Pathway 
APP-OE-up 
and AD-up 
DNA bending activity regulation of anatomical 
structure morphogenesis, 
regulation of angiogenesis, 
anti-apoptosis, 
muscle organ development  
IL2 signaling events 
mediated by PI3K,  
PDGFR-beta signaling 
pathway, 
Class I PI3K signaling 
events, 
Signaling events mediated by 















cytoskeleton organization,  
transmission of nerve 
impulse,  
cellular localization  
Transmission across 
Chemical Synapses,  
Serotonin Neurotransmitter 
Release Cycle,  
Dopamine Neurotransmitter 
Release Cycle,  
Glutamate Neurotransmitter 
Release Cycle  
 
GO analysis was performed using GREAT and the top 4-5 terms based on hypergeometric 
rank and a significance level of binomial FDR q-value < 0.05 are shown. 
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An obviously enriched group of down-regulated genes are those involved in 
‘structural constituent of cytoskeleton’, ‘intermediate filament cytoskeleton 
organization’ and ‘neurofilament cytoskeleton organization’, which is again expected 
since a number of studies have linked cytoskeletal dysregulation to AD pathogenesis. 
The specific genes involved in cytoskeletal functions that were down-regulated in the 
APP overexpression cell system, as well as in AD patient brains, include NEFL, 
NEFM, NEFH and INA (Table 17). Verification with the ChIP-Seq dataset revealed 
AICD binding sites near the TSS of these genes (Figure 24).  
Since cytoskeletal genes could be of interest, a scan of the microarray expression data 
revealed several more genes related to cytoskeletal organization that were regulated 
with APP overexpression or knockdown. TPM1, which is implicated in stabilizing the 
actin cytoskeleton, was down-regulated upon APP overexpression and up-regulated 
when APP was knocked down instead (Table 18). ACTA2, a member of the actin 
family of proteins was similarly up-regulated with APP knockdown but was not 
differentially regulated when APP was overexpressed (Table 18). Both genes were 
additionally found to be associated with AICD binding sites (Figure 24) but were not 
differentially regulated in the gene expression profile of human AD brains. Despite 
this, the contribution of these genes in AD should not be discounted based on the 
comparison with a single set of AD brain expression data. The detection of expression 
changes is usually dependent on differing experimental set-ups and systems. In any 
case, AICD seems to be down-regulating the expression of TPM1 and ACTA2 by 
binding to their promoter regions, which is consistent with the down-regulation 
observed for NEFL, NEFM, NEFH and INA. Thus, the overall repression of 
cytoskeletal genes could have some functional link to changes observed in AD.   
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Table 17. Overlapping genes down-regulated in both the APP overexpression cell line 
and human AD brain relevant to cytoskeletal organization GO terms.  









NEFL 2.8x↓ 2.2x↓ Neurofilament, light polypeptide 68kDa; 
intermediate filament protein involved in 
maintenance of neuronal caliber, functions in 
intracellular transport to axons and dendrites 
NEFM 5.0x↓ 2.0x↓ Neurofilament, medium polypeptide 150kDa; 
intermediate filament protein involved in 
maintenance of neuronal caliber, functions in 
intracellular transport to axons and dendrites, 
biomarker of neuronal damage 
NEFH 3.0x↓ 2.1x↓ Neurofilament, heavy polypeptide 200kDa; 
intermediate filament protein involved in 
maintenance of neuronal caliber, functions in 
intracellular transport to axons and dendrites, 
biomarker of neuronal damage 
INA 2.0x↓ 2.6x↓ Internexin neuronal intermediate filament protein, 
alpha; involved in the morphogenesis of neurons, 
cooperates with other neurofilaments to maintain 
neuronal structure 
 
Table 18. Cytoskeletal organization genes bound by AICD and regulated by APP 
overexpression or knockdown.  









TPM1 3.2x↓ 1.6x↑ Tropomyosin 1 (alpha); widely-distributed 
actin-binding protein, implicated in 
stabilizing cytoskeleton actin filaments 
ACTA2 --- 3.0x↑ Alpha-2 actin; belongs to the actin family of 

























Figure 24. AICD binding sites associated with cytoskeletal organization genes. ChIP-Seq 
data revealed AICD peaks that represent binding sites associated with cytoskeletal 
organization genes including NEFL, NEFM, NEFH, INA, TPM1 and ACTA2. 
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Genes that were up-regulated in both the APP overexpression cell line and human AD 
brain tissue, and were shown to be bound by AICD include DDIT4, DDIT4L and 
FOXO4 (Table 19, Figure 25). DDIT4 and DDIT4L are implicated in the mediation 
of cell death via the regulation of the mTOR signaling pathway. Similarly, FOXO4 is 
a pro-apoptotic transcription factor. Hence, it is likely that AICD could be involved in 
up-regulating genes that contribute to apoptosis in response to DNA damage and 
oxidative stress, thus playing a role in neurodegeneration in AD. 
 
 
Table 19. Overlapping genes up-regulated in both the APP overexpression cell line and 
human AD brain.  









DDIT4 2.8x↑ 1.6x↑ DNA-damage-inducible transcript 4 (also known 
as REDD1); promotes neuronal cell death and 
inhibits cell growth by regulating the mTOR 
signaling pathway 
DDIT4L 2.0x↑ 2.0x↑ DNA-damage-inducible transcript 4-like (also 
known as REDD2); mediates cell death, inhibits 
mTOR signaling pathway, 
FOXO4 1.5x↑ 2.0x↑ Forkhead box O4; member of forkhead family of 
transcription factors, induced by oxidative stress 
and contributes to apoptosis, involved in the 

















Figure 25. AICD binding sites associated with genes up-regulated in both the APP 
overexpression cell line and human AD brain. ChIP-Seq data revealed AICD peaks that 





















4.1 The AICD global chromatin binding profile supports its putative 
transcriptional activity 
To my knowledge, a genome-wide investigation of AICD transcriptional binding sites 
has never been reported. As such, even though independent studies of AICD 
modulating the transcription of specific genes have been carried out, there has been a 
lack of evidence regarding the transcriptional properties of AICD on a global level. I 
have shown here that using NGS technology, a chromatin binding profile of AICD 
can be generated to show AICD binding sites across the genome.  
The endogenous gene regulatory function of AICD has been a controversial issue in 
the field primarily due to the inconsistency in detecting the regulation of certain 
AICD targets (Aydin et al., 2011; Müller et al., 2007; Ryan and Pimplikar, 2005). 
Evidence of the AICD complex binding to genomic regions in this study should clear 
all doubts that AICD is involved in transcriptional regulation. The first clue to the 
transcriptional functions of AICD comes from the number of ‘peaks’ or binding sites 
identified, which at 21,569 and 17,917 for the respective ChIP-Seq libraries, is similar 
to the typical number of peaks from ChIP-Seq experiments (Table 7). A significant 
proportion of binding sites were distributed not only to gene promoters within 1kb of 
the TSS (~20%), but also to intergenic regions (~ 35%), suggesting that the AICD 
complex can regulate gene transcription by binding to proximal promoter regions or 
via interaction with enhancer or silencer regions distal to the TSS (Figure 9).  
Yet another indication is that active (H3K27ac) and repressive (H3K27me3) histone 
marks were found around the AICD binding sites (Figure 11), suggesting that the 
presence of AICD at particular genomic locations is associated with activated or 
repressed transcriptional activity. This is consistent with the finding that some of the 
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known AICD transcriptional targets like KAI1, Neprilysin (NEP) and p53 are up-
regulated (Alves da Costa et al., 2006; Baek et al., 2002; Belyaev et al., 2009), while 
the expression of others like EGFR and LRP1 are suppressed (Liu et al., 2007; Zhang 
et al., 2007). Although the H3K27ac- and H3K27me3-enriched genomic locations 
were derived from post-mortem brain hippocampal and cingulate gyrus tissues, and 
might not be absolutely representative of the epigenetic landscape in the SH-SY5Y-
APP cells, this analysis does provide an indication since data from brain tissues were 
used, and AICD binding sites in these human brain regions may be similar to the in 
vitro binding sites. 
In addition, AICD binding sites were detected at the promoters of BACE1, APP, 
GSK3β and EGFR, which are examples of genes under the transcriptional control of 
AICD (Kim et al., 2003; von Rotz et al., 2004; Zhang et al., 2007), showing that 
AICD interacts with chromatin for the purpose of regulating gene transcription.  
 
4.2 AICD may interact with multiple transcription factors  
The AICD complex involved in transcriptional regulation consists of AICD, Fe65 
(multi-domain adaptor protein) and Tip60 (histone acetyltransferase) (Cao and 
Südhof, 2001). However, it is not known how the complex is targeted to specific 
regulatory regions on the chromatin level since none of the complex components have 
been shown to possess sequence-specific DNA-binding activity. This study may be 
able to shed some light with regards to this knowledge gap.  
Motif search strategies revealed many consensus sequences that AICD binding sites 
are enriched for, with significant p-values (Table 8; Figure 12), suggesting that AICD 
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could work with multiple partner transcription factors in transcriptional complexes. 
As depicted in Figure 26, the genes that the complexes target for regulation will thus 
depend on the partner transcription factor involved as it determines the motif 
sequence the complex will target. As such, these transcription factors could fit the role 
of a sequence-specification component in DNA binding. 
 
 
Figure 26. Schematic of AICD complexing with different partner transcription factors. 
AICD could be directed to regulate specific target gene sets (A or B) depending on the 
transcription factor it interacts with (TF-A or TF-B), which is responsible for recruiting the 
AICD complex to the respective motifs (TF-A or TF-B).  
 
This model of AICD transcriptional control is plausible as AICD has been observed to 
interact with many binding proteins, including MINT1/MINT2 (Biederer et al., 2002) 
and JIP1b (Scheinfeld et al., 2003). This binding influences AICD transactivation of 
its target genes. Some of these AICD interactors, like the Mint family members, 
sequesters AICD in the cytosol and does not interact in a transcriptional complex at 
the chromatin level. Others, however, bind the AICD transcriptional complex and 
may hence interact with chromatin. An example is JIP1b found in nuclear AJT 
complexes with AICD and Tip60, which were morphologically different from AFT 
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complexes formed with Fe65 instead (von Rotz et al., 2004). The authors suggested 
that the nuclear spots in which AFT and AJT complexes were found might contain 
proteins and DNA important for transcriptional activity. The AFT and AJT complexes 
may also localize to different genes for transcriptional regulation since they were 
found in distinct nuclear structures. In this case, the transcriptional activity of AICD 
depended on adaptor proteins like Fe65 and JIP1b, which do not interact with 
chromatin directly.  
This is not unlike the hypothesis put forth in this study, suggesting that the genes 
regulated by the AICD complex depend on the partner transcription factors that bind 
AICD. However, these partner transcription factors are postulated to have an 
additional role of recognizing their motif sequences and binding chromatin directly, 
thus directing the AICD complex to specific chromatin binding sites. This mechanism 
of AICD transcriptional control may be represented in the regulation of GSK3β by the 
AICD-Fe65-CP2/LSF/LBP1 ternary complex, which involves the direct binding of 
the CP2/LSF/LBP1 transcription factor to the GSK3β promoter (Kim et al., 2003). 
 
4.2.1 p53 as a potential partner transcription factor 
p53 is a well-known tumour suppressor protein involved in cell cycle regulation. The 
p53 DNA binding motif was the top motif that was revealed by the known motif 
search and could partner the AICD complex in transcriptional regulation by targeting 
the complex to p53 motifs. ChIP validation experiments showed that p53 and AICD 
share common binding sites (Figure 13), which would support the hypothesis that p53 
and AICD work in the same transcriptional complex.  
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Interestingly, p53, in addition to being an AICD target (Alves da Costa et al., 2006), 
has also been reported to physically interact with nuclear AICD by co-
immunoprecipitation experiments in SH-SY5Y cells and H4 human neuroglioma cells 
(Ozaki et al., 2006). This interaction was seen to enhance the transcriptional activities 
of p53, leading the authors to propose that p53 could be present in the AFT complex 
and that it could play a role in sequence-specification for the AICD complex. 
Additionally, Tip60 has been described to physically associate to p53, although not in 
a direct manner, and act as a co-activator of p53 (Legube et al., 2004). These studies 
support a functional interaction between p53 and the AICD complex, which was 
further substantiated by our findings that p53 and AICD bind at common gene 
regulatory regions.  
The Ozaki study, at the same time, provided a clue to the functionality of this 
interaction. They showed that the interaction with p53 was crucial for AICD-mediated 
apoptosis since the increase in cell death upon the transfection of AICD was 
abrogated in p53-deficient cells. Hence, it can be proposed that the cooperation 
between p53 and AICD targets the transcriptional complex to specific regulatory 
regions of genes that contain the p53 motif and eventually affects downstream 
apoptotic processes.  
The significance of p53 as a potential partner transcription factor of AICD which co-
binds genomic regions with AICD was further substantiated by the GO analysis of 
AICD-bound and regulated genes. Cellular functions which the AICD target genes 
regulate include many p53-related functions like cell cycle regulation and DNA 
repair. This gives functionality to the p53-dependent binding of the AICD complex at 
genomic regions. The binding by p53 and AICD could thus co-regulate the 
transcription of genes that are closely-linked to p53 function, and cause downstream 
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effects on apoptosis, cell cycle regulation or DNA repair. These pathways have been 
shown to be implicated in neuronal degeneration in AD and will be discussed in detail 
subsequently. Importantly, this links the role of AICD to the development of AD. 
  
4.2.2 RBPJκ  as a potential partner transcription factor 
RBPJκ, also known as CSL (CBF1/ RBPJκ in vertebrates, suppressor of hairless in 
Drosophila, Lag-1 in C. elegans), is a sequence-specific DNA-binding protein that is 
involved in Notch signaling (Lai, 2002). It is typically present in transcriptional 
repressor complexes. However, when associated with NICD, RBPJκ recruits several 
co-activators like the Mastermind homologue MAML1-3 and switches to a 
transcriptional activator complex instead (Kopan and Ilagan, 2009), leading ultimately 
to the regulation of developmental processes and adult tissue homeostasis.  
The identification of the RBPJκ motif within the top de novo motif hints at the 
possibility that both RBPJκ and AICD could be involved in the transcriptional 
regulation of a specific subset of genes. In a genome-wide study, Wang et al. (2011) 
compared the Notch1 and RBPJκ binding sites in T-lymphoblastic leukemia cells and 
observed that a significant portion of genomic sites only bound RBPJκ and not NICD 
even though the latter was present. Possible explanations suggested by the authors are 
that RBPJκ may also regulate transcription without the involvement of NICD, or that 
NICD may not have had access to the binding sites due to competitive binding of 
other co-repressor complexes. As such, the NICD-independent RBPJκ transcriptional 
control might involve AICD instead, and it could act as a co-factor that competes with 
NICD for binding. Consistent with the idea that RBPJκ may work with transcriptional 
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modulators other than NICD, EBNA2 (Epstein-Barr virus nuclear antigen 2) has also 
been found to associate with RBPJκ to activate its transcriptional activity (Grossman 
et al., 1994; Henkel et al., 1994). Thus, RBPJκ could be involved in different 
transcriptional programmes depending on the co-activators or co-repressors like 
NICD, EBNA2, or possibly AICD that it complexes with. 
The crosstalk between AICD and NICD adds a new dimension to their relationship 
with RBPJκ. AICD was shown to down-regulate NICD signaling by facilitating the 
degradation of NICD and RBPJκ by the Fbw7-dependent proteasomal pathway and 
the lysosomal pathway respectively (Kim et al., 2011). Conversely, NICD was also 
observed to interact physically with the AFT complex to suppress transcriptional 
signaling by the complex (Kim et al., 2007). This seems to indicate that AICD and 
NICD have antagonistic properties and negatively regulate each other’s 
transcriptional functions. Taken together with the fact that NICD acts as a 
transcriptional co-activator of RBPJκ and the possibility that AICD acts with RBPJκ 
in a transcriptional complex as well, it is likely that NICD and AICD compete with 
each other for binding to RBPJκ. This is supported by co-immunoprecipitation 
experiments showing the interaction between AICD and RBPJκ (Kim et al., 2011). 
However, the interaction was shown in the context of AICD facilitating the 
degradation of RBPJκ and does not associate the complex to chromatin-binding and 
gene regulation. This study shows additionally that RBPJκ and AICD co-bind certain 
gene regulatory regions, suggesting the transcription regulation-related functions of 
the interaction and strengthening the likelihood of a transcriptional model involving 
RBPJκ, NICD and AICD. 
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4.3 Cellular functions represented by AICD-bound and regulated genes 
4.3.1 Cell cycle 
A group of GO terms that is related to cell cycle control came up most frequently for 
genes that are bound and regulated by AICD. For example, ‘cell cycle phase’ and 
‘mitotic cell cycle’ came up for the APP knockdown down-regulated genes while 
‘regulation of transcription involved in G1/S phase of mitotic cell cycle’ came up for 
the APP overexpression down-regulated genes (Table 11). Cell cycle control thus 
seems to be intricately implicated in the biological processes downstream of AICD 
transcriptional control.  
Not only were AICD binding sites found within 20kb of cyclins B1, B2 and E1, their 
mRNA levels were also found to be lowered upon APP knockdown (Table 12). 
Conversely, CDK6 levels were elevated when APP was overexpressed. CDK 
inhibitors like CDKN1A and CDKN1C were both similarly bound by AICD and 
differentially regulated by elevated and suppressed APP levels (Table 12). However, 
the direction of regulation was not consistent as CDKN1A was up-regulated with 
APP knockdown, unlike the general trend of CDK inhibitor down-regulation and up-
regulation with APP knockdown and overexpression respectively. Such findings were 
consistent with the fact that cell cycle activation genes, cyclins B1 and D1, were 
previously identified to be up-regulated by AICD via a transcriptional mechanism in 
differentiated PC12 cells and rat primary cortical neurons (Ahn et al., 2008). AICD 
could thus transcriptionally regulate cell cycle activators like cyclins and CDKs, as 
well as inhibitors of cell cycle progression like CDK inhibitors. 
Interestingly, the dysregulation of cell cycle genes has been implicated in AD 
neurodegeneration. CDKs and cyclins have been shown to be re-expressed in neurons 
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in AD. CDK7 levels were found to be elevated in hippocampal neurons of AD 
patients (Zhu et al., 2007) while other CDKs like CDK4 and CDK2 were up-regulated 
as well (Arendt et al., 1996; McShea et al., 1997). In a similar fashion, aberrant 
cdc2/cyclin B1 expression was detected in AD neurons that were observed to 
accumulate NFTs (Vincent et al., 1997). Correspondingly, the expression of cyclin B 
and E was accentuated in AD patients according to previously published data (Nagy 
et al., 1997). CDK inhibitors which function in cell cycle arrest are similarly 
dysregulated in AD neurons. The levels of p27, a CDK inhibitor, were increased in 
AD patients as compared to control subjects, reflecting a greater effort to arrest the 
abnormal return to the cell cycle as observed by the authors (Ogawa et al., 2003). 
Induction of other CDK inhibitors like p16, p19 and p21 was also observed in AD 
(Arendt et al., 1998; Park et al., 1998). 
It is no surprise then that the involvement of cell cycle control agrees with current 
speculation that AD is in fact a disease that has its roots in the dysregulation of cell 
cycle functions. More specifically, widespread neuronal degeneration observed in AD 
brains could be due to terminally differentiated, post-mitotic neurons that are 
abnormally sensitized to mitotic stimuli, resulting in their re-entry of the cell cycle 
and loss of neuronal properties, much like a de-differentiation process (Raina et al., 
2000). However, the process is arrested before the cell can complete the cell cycle in 
full, leading to apoptotic cell death of the mitotically incompetent cells (Bowser and 
Smith, 2002). Hence, the AICD-dependent changes in the expression of cell cycle 
control genes can be associated to cell cycle dysregulation observed in AD.  
Generally, the trend of cell cycle gene changes in this study is in agreement with 
previous observations as described. However, there is a lack of consistency with 
regards to the direction of regulation of some of these cell cycle genes, which could 
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be due to additional fine-tuning mechanisms that may occur in a system that is 
regulated on multiple levels. There are likely compensatory mechanisms in place to 
counteract the aberrant activation of cell cycle progression, which would mask the 
direct effects of AICD transcriptional regulation. 
‘Polo-like kinase signaling events in the cell cycle’ was identified as a significant 
pathway in the GO analysis for genes that showed a reduction in expression with APP 
knockdown. Some examples of genes that are involved in the polo-like kinase (Plk) 
pathway include CDC20, CDC25C and PLK4, which were all down-regulated upon 
APP knockdown. Plk is essential for mitotic progression, and phosphorylates its 
substrate, CDC25, for further activation of mitosis. As such, the possibility of this 
pathway being up-regulated by AICD provides another piece of evidence for the role 
of AICD in the cell cycle re-entry of neurons. Indeed, this was corroborated by 
studies showing an increase in Plk levels in hippocampal and cortical neurons of AD 
patients (Harris et al., 2000; Song et al., 2011). 
  
4.3.2 DNA repair 
Closely-linked to cell cycle regulation are processes like ‘cellular response to stress’, 
‘response to DNA damage’ and ‘DNA repair’, which are enriched GO terms for 
down-regulated genes triggered by an overexpression of APP. Appropriately, a 
reduction in expression in the presence of AICD for genes like PCNA, FANCD2, 
DTL, APITD1 and FOXM1 that are involved in DNA repair and damage response 
were observed (Table 13). As these genes are bound by AICD, AICD might be 
influencing their related functions directly.  
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These results may give further support to the hypothesis that DNA repair deficiency 
compromises DNA integrity by causing the accumulation of DNA damage, leading to 
neuronal degeneration in AD (Mazzarello et al., 1992). Consistent with this 
hypothesis are findings that DNA repair activity was lowered in sporadic and familial 
AD patients (Boerrigter et al., 1992; Jones et al., 1989; Parshad et al., 1996). DNA 
repair is inevitably associated with levels of DNA damage, which has been suggested 
in many studies to play an important role in not just AD, but other neurodegenerative 
diseases as well (Cotman et al., 1996; Itzhaki et al., 1994; Robison et al., 1984). 
Indeed, a study comparing the levels of DNA damage in neuronal tissues of AD 
patients to normal patients showed increased DNA breaks in the AD brains (Mullaart 
et al., 1990). The observed accumulation of DNA damage in AD could very well be a 
consequence of the DNA repair deficiencies, as the neurons become less competent in 
correcting damaged DNA perhaps due to the reduced expression of molecules key to 
the DNA repair process.  
For such a multifaceted disease, AD pathogenesis could be regulated on multiple 
levels and it is difficult to decipher where the pathogenic process actually stems from. 
The failure in DNA repair could be a direct cause of DNA damage in neurons in AD 
brains. However, a more likely possibility would be that there is, at the same time, a 
larger extent of DNA damage from oxidative stress and free radical damage 
(Markesbery, 1997; Perry et al., 1998; Smith et al., 1995), such that the DNA repair 
mechanisms are overwhelmed and unable to cope. A main source of free radicals and 
oxidative stress is the mitochondria. When the cell cycle is arrested before it 
completes the mitosis stage, there is an accumulation of excess mitochondria which 
contributes to the oxidative stress and DNA damage (Raina et al., 2000). This, when 
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compounded with the reduced capacity for DNA repair, could explain downstream 
neuronal degeneration in AD. 
I have shown here that AICD could be a key molecule that contributes to the 
pathogenic process of AD, by means of transcriptionally down-regulating DNA repair 
genes and compromising the ability of neurons to undergo DNA damage repair. These 
processes may occur in conjunction with cell cycle dysregulation in neurons to lead to 
the degeneration of neurons.  
 
4.3.3 Apoptosis 
As mentioned previously, evidence has shown that when cell cycle control becomes 
dysregulated in neurons, they become re-sensitized to molecular signals and re-enter 
the cell cycle. However, stasis sets in as the cells seem to suffer incomplete phase 
transition through the cell cycle. This could trigger downstream apoptotic signals. In 
fact, many studies have linked AICD to the activation of apoptosis (Kinoshita et al., 
2002; Müller et al., 2007; Passer et al., 2000). p53 and GSK3β are two specific 
mediators of apoptosis that AICD directly regulates (Alves da Costa et al., 2006; Kim 
et al., 2003).  
Although ‘apoptosis signaling pathway’ was one of the terms enriched in the GO 
analysis for bound and regulated AICD target genes, it was represented by genes like 
CASP7, MAPK9 and TP53 that were down-regulated upon APP overexpression 
(Table 14). This is seemingly contrary to previous reports linking AICD to the 
activation of apoptosis. Conversely, expression of BCL2, a suppressor of apoptosis, 
was decreased upon APP overexpression instead, further confounding the trend of 
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observations. However, many of the differentially regulated apoptotic genes like 
HSPA5, HSPA1A and HSPA1B, or even TP53, are implicated even in pre-apoptotic 
stages in response to stress-induced damage and are not specific indicators of changes 
in the apoptotic process. Hence, observed changes in expression of the genes 
identified to be part of the apoptotic process in this study are insufficient for us to 
conclude that apoptotic regulation is indeed implicated in AICD signaling. 
Furthermore, the known positive regulatory effect of AICD on p53 (Alves da Costa et 
al., 2006) seems to have been reversed under our APP overexpression conditions. A 
point to note, however, is that even though there was a drop in the level of p53 
expression, the overall genes involved in the p53 pathway was up-regulated, as 
indicated in the enriched GO terms (Table 14). This indicates that AICD exercises 
control over the p53 pathway, even though effects of its transcriptional regulation on 
apoptotic processes in general is unclear. Another likelihood is that AICD may only 
enhance some, but not all, aspects of the p53 pathway.  
Apoptosis, however, is thought to play a role in the development of AD, as indicated 
by massive degeneration of neurons in sufferers of AD. It is thought to be an endpoint 
of cell cycle dysregulation in affected neurons. Accordingly, both DNA damage and 
caspase activity were enhanced, while the expression of other genes relevant to 
apoptosis, such as Bcl-2 family members and DNA damage response genes were 
altered in AD patient brains (Masliah et al., 1998; Su et al., 1994). The 1.5 times 
increase in the expression of p53 transcripts in AD patient brains (Tan et al., 2010) 
further indicate that p53-dependent apoptosis could have a role in AD pathogenesis.  
Nonetheless, the involvement of apoptosis is still an issue of some controversy as 
there have indeed been reports questioning the extent of apoptosis in AD. It has been 
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found that very few neurons, possibly fewer than 1/10000, actually undergo apoptosis 
at a point in time (Perry et al., 1998). Thus, it has been suggested that instead of 
undergoing acute apoptosis, cells adapt to a moderate level of oxidative stress in AD 
and therefore, neuronal loss is not massive (Zhu et al., 2001). This is consistent with 
AD being a chronic, protracted disease with gradual loss of neurons over many years.  
The minimal detection of apoptotic signals, as corroborated by APP-overexpressing 
SH-SY5Y cells not showing overt signs of massive cell death in their morphology, 
could simply suggest that AICD alone does not regulate apoptosis directly, although 
experiments to quantify apoptosis in these cells were not carried out. Rather, other 
factors contributing to AD pathogenesis could have a hand in apoptotic development. 
Alternatively, apoptosis may be an event that is further downstream of the 
dysregulation observed in the SH-SY5Y-APP cells and its processes may not be 
accurately reflected at the particular stage the cells were at. The cells may have 
entered an adaptive phase where AICD downstream signaling does affect genes that 
control cell cycle progression, including the p53 pathway, and genes that reduce the 
capacity for DNA repair. It is more likely, then, that AICD targets directly the genes 
that are upstream of the apoptotic process, such as cell cycle control genes, and that 
apoptosis could merely be a subsequent effect.  
 
4.3.4 Diabetes signaling 
Another interesting finding was the enrichment in diabetes pathway genes in the 
bound and regulated AICD target genes. Three IGF-binding proteins, IGFBP-4, -5 
and -6, were found to be down-regulated by about 2 or more folds under conditions 
that cause an overexpression of AICD (Table 15), and also had AICD binding sites 
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associated with their genes (Figure 22). IGF-binding proteins play a role in 
sequestering secreted IGFs and either inhibit their interaction with their cell surface 
receptors for downstream activation of the insulin signaling pathway, or prevent the 
clearance of the IGFs (Holly and Perks, 2006). IGF-binding proteins thus modulate 
the activity of IGFs, which was shown to be affected in AD patients (Salehi et al., 
2008). Here, it was shown that AICD is implicated in the regulation of some of the 
IGF-binding proteins, which could explain some of the insulin pathway changes 
observed in AD. Studies have indeed shown that insulin and IGF-1 are potentially 
involved in neurodegenerative diseases like AD (Gasparini et al., 2002). Since insulin 
acts as a trophic factor in the brain that is important for insulin-dependent homeostasis 
pathways, the dysregulation could be detrimental to neuronal survival. 
It has long been suspected that diabetes is linked to AD. This speculation stems from 
the observation that patients suffering from diabetes mellitus are more susceptible to 
developing AD (Arvanitakis et al., 2004; Peila et al., 2002). In a detailed study about 
the association between the two diseases, researchers have found that the risk of 
adults with diabetes developing AD is more than double that of non-diabetics (Ohara 
et al., 2011). A very recent study has further strengthened this link as the authors 
hypothesize that the increased risk to AD is due to an increase in resistance against 
brain insulin and IGFs, resulting in the rise in ceramide levels, which in turn activates 
ER stress and apoptotic pathways in the brain (de la Monte et al., 2012). 
De la Monte (2012) posits that neurodegeneration in AD can progress via two 
pathways with respect to insulin. Firstly, in the extrinsic pathway, ceramides 
accumulated as a result of insulin resistance outside of the brain can pass the blood-
brain barrier and cause insulin resistance and inflammation in the brain. An 
alternative intrinsic pathway, which involves the endogenous development of brain 
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insulin resistance via the dysregulation of insulin signaling pathways in the brain 
itself, could be regulated by AICD. It is also possible that the regulation by AICD is a 
feedback mechanism that interlinks the diabetes-relevant pathways to molecular 
mechanisms that can explain AD pathogenesis. 
 
4.3.5 Cytoskeletal dynamics 
Genes related to cytoskeletal organization were found to be down-regulated upon the 
overexpression of APP. Genes encoding neurofilaments like NEFL, NEFM, NEFH 
and INA were 2-to 5-fold down-regulated (Table 17). NEFL, NEFM, NEFH and INA 
were not only differentially regulated under conditions of AICD overexpression, but 
are likely to be direct transcriptional targets of AICD since AICD binding sites were 
found near their transcriptional start sites (Figure 24). This was in agreement with a 
genome-wide study of gene expression alterations in AD patients (Tan et al., 2010), 
in which the same four genes showed a down-regulation of more than 2-fold on 
average (Table 17). Other than Tan et al. (2010), there have been other reports of 
neurofilaments being down-regulated in AD brain tissues (Kittur et al., 1994; 
McLachlan et al., 1988).  
The cytoskeletal network in neurons are predominantly made up of neurofilaments, 
which have important roles in maintaining neuronal caliber and in intracellular 
transport to the axons and dendrites. The NEFL, NEFM and NEFH genes encode the 
neurofilament light, medium and heavy subunits respectively. Dysregulation of the 
cytoskeletal network has commonly been linked to AD pathology, as cytoskeletal 
proteins like tau and neurofilament proteins were found to be hyperphosphorylated 
and accumulated in NFTs (Perry et al., 1985), one of the hallmarks of AD. As such, 
 113 
McLachlan et al. (1988) hypothesized that the decrease in expression of the 
neurofilament light subunit, which could be due to transcriptional inhibition of NEFL, 
is instrumental in the destabilization of neurofilament homeostasis. Thus, this may 
trigger the abnormal accumulation of filaments commonly observed in cytoskeletal 
dysregulation. In agreement, the typical configuration of cytoskeletal components like 
actin filaments was lost and seen to clump at the cell periphery instead when AICD 
and Fe65 were both overexpressed (Müller et al., 2007). Taken together, since AICD 
binding sites were found near the neurofilament genes, AICD could directly bind and 
down-regulate neurofilament genes, leading to the disruption of homeostatic levels of 
cytoskeletal proteins. This then causes structural alterations in the cytoskeleton and 
promotes the accumulation of fibrils, which ultimately form intracellular NFTs.  
In the Müller et al. (2007) study, although cytoskeletal dynamics were modulated by 
the overexpression of AICD and Fe65, there were several differences in gene 
expression changes in some of the cytoskeletal genes as compared to the changes seen 
in this study. Firstly, neurofilaments were not found to be differentially regulated by 
Müller et al. (2007). Instead, other cytoskeletal genes like α2-actin, transgelin and 
tropomyosin 1 were up-regulated, contrary to the general trend of down-regulation of 
tropomyosin 1 and α2-actin upon APP overexpression (Table 18). This difference 
could be due to the difference in cell systems; the authors used an inducible cell 
system in which AICD and Fe65 were both overexpressed, as opposed to APP 
overexpression in this study. Despite the disparity, a common conclusion with respect 
to the disruption of homeostasis in cytoskeletal dynamics can be drawn, linking AICD 
to AD pathogenesis. However, more investigation into the mechanism of cytoskeletal 
dysregulation by AICD is necessary for a clearer picture. 
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4.3.6 The link to tau 
Tau, a component that forms NFTs, a second neuropathological hallmark of AD, is 
known to play a role in the intricate network of AD pathogenesis. Tau is a 
microtubule-binding protein that is abnormally hyperphosphorylated in AD patients, 
forming intracellular lesions known as NFTs. APP or Aβ have been shown to play a 
role in NFT generation by interacting with tau (Lewis et al., 2001). However, it has 
been suggested that Aβ per se has limited correlation with tau pathology (Simón et 
al., 2009). In an attempt to address this, AICD was instead presented as another 
possible protein that causes tau pathology, as observed in AICD transgenic mice that 
displayed Aβ-independent tau aggregation (Ghosal et al., 2009). 
Interestingly, tau mRNA levels were up-regulated by approximately 1.7 times with 
APP overexpression, and the MAPT gene which encodes the tau protein was also 
bound near its TSS by AICD, as observed from the ChIP-Seq data. This is consistent 
with previous suggestions that AICD may be responsible for tau pathology and adds 
to this hypothesis the possibility of AICD being involved directly in the 
transcriptional modulation of tau.  
Furthermore, DnaJA1, a member of the DnaJ/Hsp40 family of chaperone proteins, 
was about 1.9 times down-regulated when APP was overexpressed. DnaJA1 acts as a 
co-chaperone of the Hsp70 (heat shock protein 70) variant, Hsc70 (heat shock cognate 
70), which is involved in tau-dependent microtubule polymerization (Jinwal et al., 
2010). In a recent finding, DnaJA1 levels were inversely correlated to tau levels both 
in vitro and in vivo, as DnaJA1 mediates the clearance of tau possibly via ubiquitin-
dependent pathways (Abisambra et al., 2012). This agrees with our findings that 
under conditions of AICD overexpression, DnaJA1 was down-regulated and tau up-
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regulated. Hence, AICD is perhaps responsible for tau accumulation via direct 
transcriptional control on two levels, directly via the regulation of MAPT itself and 
indirectly via modulation of DNAJA1. 
Given the inter-relatedness of the biological processes that are dysregulated in AD, it 
is not surprising that tau alterations also lead to cell cycle re-entry in both Drosophila 
and mouse tauopathy models (Delobel et al., 2006; Khurana et al., 2006). 
Particularly, Khurana et al. showed that cell cycle activation is a downstream effect of 
tau alterations and eventually leads to tau-induced neurodegeneration via the 
activation of the TOR (target of rapamycin kinase) pathway.  
 
4.4 Limitations and future directions 
AD is a complex disease that obviously involves many inter-related biological 
processes and cellular functions possibly regulated on multiple levels by different 
molecular mechanisms. In this study, the involvement of AICD was investigated and 
cellular functions like cell cycle control and DNA repair were found to be affected. 
However, intricate compensation mechanisms that attempt to bring the cell back to its 
original state may be involved upon changing levels of cellular AICD. This probably 
explains some of the contradicting gene expression changes in this study.  
Additionally, gene regulation occurs on multiple levels in a cell. For example, post-
translational modifications like phosphorylation can change the functional 
conformation of a protein and result in varying protein-protein interactions that affect 
downstream signals in a different manner. As such, gene expression changes based on 
mRNA levels is probably not a sufficient measure of changing cellular functions in a 
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cell. A case in point is the decrease in p53 levels upon APP overexpression even 
though the overall p53 pathway was up-regulated instead. p53 has even been shown 
to contribute to non-apoptotic functions like axonal outgrowth and regeneration via 
different post-translational pathways (Di Giovanni et al., 2006; Tedeschi and Di 
Giovanni, 2009). Hence, the sole decrease in p53 levels does not entirely reflect the 
direction of change in biological processes.  
Moreover, the in vitro APP overexpression and knockdown systems were purely 
meant to simulate varying levels of AICD and does not by any means represent 
changing cellular functions in AD in its entirety. Hence, it is possible that some 
immediate gene expression changes appear to be counter-intuitive with respect to AD. 
It is important to acknowledge as well, that the overexpression of APP instead of 
AICD could result in confounding effects from other cleavage products of APP, at 
least in the gene expression profiles. However, these confounding effects should, in 
theory, have been eliminated by comparison to the AICD binding profile since 
transcriptional regulatory functions have not been observed for any other APP 
cleavage products.  
Lastly, gene expression changes in response to AICD seem to be largely dependent on 
cell systems. For example, previous studies have reported the lack of differential 
regulation upon AICD and Fe65 overexpression for known AICD targets like KAI1, 
GSK3β, APP and Neprilysin in SHEP-SF neuroblastoma cells and in AICD/Fe65 
transgenic mice (Müller et al., 2007; Ryan and Pimplikar, 2005). Again, careful 
distinctions have to be made between the overexpression of APP and of AICD. The 
SH-SY5Y cell line was chosen for ease of transfection and handling in large numbers, 
which is required for the ChIP experiments. It is also widely used in AD- and AICD-
related studies, which could provide better grounds for comparison. This would have 
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been difficult if primary neural cell lines or even AD patient cells were used instead. 
Moreover, it is always possible to validate the experimental findings from the SH-
SY5Y cell line in a more physiologically relevant system later on. 
Clearly, it is necessary to carry out further investigations to make more definite 
conclusions about the genes that are directly bound and regulated by AICD, and the 
cellular functions that they subsequently affect. AICD chromatin binding sites can be 
validated using luciferase assays and the expression regulation of specific candidate 
genes validated in differentiated cell lines, primary neuronal cultures or in vivo 
systems of higher physiological relevance. AICD transgenic mice would be a likely in 
vivo model suitable for validation studies. However, lack of reproducibility in 
validating targets identified in a human cell line in a mouse model can be expected. 
Additionally, the limited selection of genomic regions confirmed to be co-regulated 
by AICD and p53/RBPJκ could be further expanded to include an investigation of all 
co-regulated genomic regions. This can be achieved by performing ChIP-Seq 
experiments for p53 and RBPJκ, and identifying overlaps of p53-bound or RBPJκ-
bound regions with AICD-bound regions. A more in-depth analysis of the 
mechanisms of co-regulation by AICD and its partner transcription factors can then 








In this study, I set out with the objective of mapping AICD transcriptional targets on a 
genome-wide basis. This was achieved using ChIP-Seq to reveal the binding profile 
of the AICD complex, complemented with microarray analysis to identify functional 
binding sites that led to the differential expression of genes upon AICD regulation. 
Through a motif search for a possible consensus sequence that AICD recognizes, it 
was found that AICD possibly recognizes and binds to a number of different 
consensus sequences in association with different partner transcription factors. p53 
and RBPJκ were found to co-bind AICD binding sites respectively and could interact 
with AICD in a transcription regulation complex. As AICD-bound and regulated 
genes were observed to be enriched in cellular functions like cell cycle control and 
DNA repair, which are closely-linked to p53 functions, the AICD/p53 co-regulation 
of genes could be responsible for changes in these cellular functions. It was 
interesting that many of the cellular functions found to be regulated by AICD are 
associated with changes observed in AD neurodegeneration, suggesting that AICD 
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